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API Active Pharmaceutical Ingredient  
BPR Back Pressure Regulator  
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C2 2nd step of convergent synthesis of rufinamide 
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L2 2nd step of linear synthesis of rufinamide 
L3 3rd step of linear synthesis of rufinamide 
LED Light Emitting Diode 
Li-1 1st step of synthesis of lidocaine 
Li-2 2nd step of synthesis of lidocaine 
MFC Mass Flow Controllers 
MIDA N-methyliminodiacetic acid 
n-BuLi Normal butyllithium 
NMP N-methyl-2-pyrrolidone 
NMR Nuclear Magnetic Resonance 
OD Outer Diameter 
P1 1st step of photochemical process 
P2 2nd step of photochemical process 
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RDS Reagent Delivery System 
R-C Reagent delivery system – Collection 
R-R Reagent delivery system - Reagent delivery system 
R-S Reagent delivery system – Standby module 
S-C Standby module - Collection 
S-R Standby module - Reagent delivery system 
S-S Standby module - Standby module 
SM Standby Module 







Automation of organic synthesis has seen rapid progress in the past decade with 
the development of many platforms for execution, investigation and optimization of 
chemical reactions and multistep processes. Each of these platforms relies on a different 
approach to chemical synthesis; including traditional batch chemistry, solid-phase 
synthesis and flow chemistry, and uses a different dedicated hardware to translate and 
operate processes. The aim of this thesis was to identify both strengths and limitations of 
the existing synthesizers and to develop a new platform based on a hybrid approach that 
takes the best elements from each of them.  
First, the radial paradigm was established; a new arrangement of reaction modules 
that allows for their reuse within the same process, uses discrete volumes of solutions and 
decouples reaction steps so that each reaction in a multistep synthesis can be performed 
at optimal conditions, minimizing the waste of materials and equipment required (chapter 
1, section 1.4). The hardware of the instrument is described thoroughly in chapter 2 with 
details of each module (broken down into its basic components), explanation of the 
possible flow pathways, troubleshooting and calibration data.  
Once the hardware was assembled, the radial synthesizer was validated by 
performing a series of showcase processes (chapter 3). First, convergent and linear 
syntheses of the active ingredient rufinamide were chosen to demonstrate the capability 
of switching between different synthetic routes without the need for physical 
rearrangement of the instrument (section 3.1). Second, a library of twelve derivatives was 
generated within a short amount of time and minimum waste of starting materials to show 
the potential of the radial synthesizer for a possible application in medicinal chemistry 
(section 3.2). Next, the synthetic and analytical capabilities of the instrument were 
expanded by integrating a module for photochemistry and flow-NMR spectroscopy via 
standard flow connectors (section 3.3). Finally, radial synthesis and continuous flow 
synthesis were compared by preparing three pharmaceutical ingredients (paracetamol, 
lidocaine, and nifedipine), developing and optimizing each step in the radial synthesizer 





Die Automatisierung der organischen Synthese hat in den letzten zehn Jahren mit 
der Entwicklung vieler Plattformen zur Ausführung, Untersuchung und Optimierung 
chemischer Reaktionen und mehrstufiger Prozesse rasante Fortschritte erzielt. Diese 
Plattformen basieren auf verschiedenen Ansätzen um chemische Synthesen mittels 
Batch-Verfahren, Festphasensynthese, oder der Druchflusschemie vollautomatisch 
durchzuführen. Die unterschiedlichen Strategien benötigen jeweils spezielle Hardware. 
Das Ziel dieser Doktorarbeit war es, die Stärken und Schwächen der vorhandenen 
Automatisierungsmethoden zu identifizieren und eine neue Plattform zu entwickeln, die 
die Vorteile der jeweiligen Strategien kombiniert.  
Aufgrund dieser Analyse wurde ein radialer Syntheseautomat konzipiert. Eine 
neue Anordnung von Reaktionsmodulen ermöglicht diese, innerhalb desselben 
Prozesses, mehrmals zu verwenden. Durch diskrete Lösungsvolumina und entkoppelte 
Reaktionsschritte kann jede Reaktion in einer mehrstufigen Synthese unter optimalen 
Bedingungen durchgeführt werden, wodurch die Verschwendung von Chemikalien und 
Ausrüstung minimiert wird (Kapitel 1, Abschnitt 1.4). Die Hardware des entwickelten 
Syntheseautomaten wird in Kapitel 2 ausführlich beschrieben. Dies umfasst die 
Grundkomponenten jedes Moduls, Erläuterungen zu möglichen Durchflusswegen, 
Fehlerbehebung und Kalibrierungsdaten.  
Der radiale Syntheseautomat wurde anhand mehrerer mehrstufiger Synthesen 
validiert (Kapitel 3). Zunächst wurden konvergente und lineare Synthesen des Wirkstoffs 
Rufinamid durchgeführt, um zu veranschaulichen, dass der Syntheseautomat im Stande 
ist zwischen verschiedenen Synthesewegen zu wechseln eine der Hardware 
vorzunehmen (Abschnitt 3.1). Zudem wurde eine Bibliothek mit zwölf Derivaten von 
Rufinamid erstellt, um das Potenzial des Syntheseautomaten für die Anwendung 
Anwendung in der medizinischen Chemie aufzuzeigen (Abschnitt 3.2). Anschließend 
wurden die synthetischen und analytischen Möglichkeiten des Instruments durch die 
Integration eines Moduls für Photochemie und eines Moduls für Durchfluss-NMR-
Spektroskopie erweitert (Abschnitt 3.3). Schließlich wurde die „radiale Synthese“ mit der 
kontinuierlichen Druchflusssynthese für die Herstellung von drei pharmazeutischen 
Wirkstoffen (Paracetamol, Lidocain und Nifedipin) verglichen. Jeder Reaktionsschritt 
wurde im radialen Syntheseautomat entwickelt und optimiert. Anschließend wurde eine 
Skalierung der entwickelten Syntheseroute im Gramm-Maßstab in einem kontinuierlichen 
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1.1 Chemistry in the era of automation 
Our world relies on automation for applications ranging from the simplest task, like 
a traffic light controlling vehicle movement at an intersection, to extremely complex control 
systems managing industrial plants, telecommunications, and spacecrafts. In principle, 
every situation in which a machine could replace a human being´s action can be improved 
or facilitated by automation. Repetitive tasks, in particular, benefit the most from being 
automated, because a machine can be faster, more efficient, and more reproducible 
accomplishing them, than a human operator, thus resulting in labor and time savings. 
Since the advent of assembly lines, work is repetitively performed from workstation to 
workstation, for instance, in manufacturing plants, where processes are now automated 
as robotic assembly lines in which human intervention is required only for the definition 
and supervision of the protocols, and the “manual” work is left to the machines.  
The technological transformation of the world has affected the field of chemistry 
too. At the laboratory level, thermostatic baths, centrifuges, and autosamplers are so 
deeply rooted in our routine that we barely notice them at all. Not only routine operations, 
but also more complex matters such as organic synthesis have been turning towards 
automation. Replacing the operator, when it comes to synthetic chemistry, is not trivial, 
because synthetic processes are composed of a huge number of diverse chemical 
transformations, achievable through an even bigger number of manual operations, which 
can be linked together in a countless number of combinations. Therefore, it is difficult to 
treat it like an assembly line and break it down in workstations which can be run by 
machines.  
Aside from the operational complexity, chemistry itself poses some intrinsic 
hurdles, such as manipulation of toxic/corrosive species, rational tuning of many different 
variables, and integration of precise yet robust analytical methods. Thus, every process 
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results in a set of different complications that must be addressed as a unique challenge. 
As a direct consequence of this uniqueness, it is extremely difficult to conceive of a 
universal machine for chemical synthesis. Although robots (defined in the collective 
imagination as machines capable of moving independently and performing complex 
actions) might seem the most obvious choice to meet this goal, as they are the closest we 
can get to the artificial version of a fully operative human being, their complexity is often 
excessive for what is the actual task.  
Automation cannot simply mean letting a robot performing processes the exact 
same way a human operator would. The process of automating a task inevitably alters the 
task, simplifying it at its core1. The ultimate goal of automation, aside from disburdening 
people from mere and tedious jobs, is to outperform humans in productivity, reproducibility, 
and reliability.  
Robots intended as humanoid machines (or machines which mimic parts of a 
human body e. g. robotic arms) have some of the same limitations of humans, while being 
less flexible and more complex. For this reason, aside from a few examples of batch 
approaches relying on robotic systems2,3, when it comes to the automation of chemical 
synthesis, the attention is generally turned to flow chemistry4,5 or solid-phase chemistry6-8, 
which are powerful techniques capable of streamlining synthetic operations and which 
require much simpler hardware and software than robots.  
1.2 Flow microreactors enabling new chemistries and multistep synthesis 
Currently, flow chemistry is a widely studied field, with many researchers looking 
to it for a convenient way to automate processes providing reproducible access to a range 
of chemistries that are otherwise inefficient or problematic9.  
At its core, a flow process is composed of a continuous stream of a solution 
containing reagents, delivered by pumps and combined at a mixing junction, passing into 
a reactor unit to which specific conditions are applied. After a defined amount of time, the 
reaction mixture leaves the reactor unit and can have several different fates such as 
collection, utilization in a following step by flowing in another unit, such as a purification 




Figure 1.1. Breakdown of the basic components of a continuous flow system.  
 
Organic synthesis has considerably benefited from the advent of flow chemistry. 
The integration of flow technology has contributed to paving the way for the development 
and application of photochemistry in synthesis10 and for accessing unstable, reactive 
species, which can be generated in-situ in flow11, in a safe and reproducible manner, 
resulting in cleaner and more efficient processes.  
Thanks to the small reactor volumes, good control over temperature and residence 
time and resistance to high pressure, flow processes have proven to be safer, more 
selective, and greener than traditional batch chemistry. Running reactions in sealed, 
pressurized systems allows for working with solvents above their boiling points, while the 
extensive surface-to-volume ratio of microreactors ensures good heat transfer, thus 
providing the opportunity of applying rapid temperature ramps with certainty that the same 
temperature is applied simultaneously to the entire flowing solution with negligible 
gradient. For endothermic reactions, this means that it is possible to shorten the reaction 
time from several hours to minutes, and for highly exothermic reactions, that it is possible 
to circumvent the use of cryogenics by exploiting the good heat dissipation offered by the 
narrow tubes. The extremely fast mixing offered by microreactors also plays an important 
role, especially when it comes to harnessing very fast reactions which traditionally suffer 
12 
 
from product selectivity. Micromixing shortens the diffusion path improving the control on 
kinetics12. 
One often underestimated but very important feature of flow chemistry is the direct 
correlation between reaction time and physical position in flow reactors. In a given reactor, 
the reaction time (a concept that translates into residence time when switching from batch 
to flow) is a function of flow rate and volume, which is itself the result of two factors: tube 
diameter and length. Once the system has reached its steady state, the reaction progress 
in every part of the reactor is constant, with the new species forming along the length of 
the fluid path. The implications of this space-time analogy are significant, particularly for 
fast reactions or those proceeding through reactive intermediates, for which it is possible 
to define a spatial position in the reactor. When one writes out a reaction, reagents are 
drawn coming together, creating an intermediate such as an organolithium species that 
then reacts e.g. with an electrophile to give the desired product. Traditionally, all these 
species are present together presenting multiple potential reaction pathways, including the 
formation of side products. In an attempt to control the reaction selectivity cryogenic 
conditions are often required. However, flow modules can be designed to create a system 
that reflects the elementary steps of a reaction, including the physical position of its 
intermediates, similar to the way it is drawn (Figure 1.2). Thereby, short living and highly 
reactive species can be reproducibly formed and harnessed in flow more efficiently and 
safely than in batch13.  
 
Figure 1.2. (top) A typical example of how chemists write out a reaction. (bottom) flow generation 
of an organolithium. The reactive species is generated cleanly and delivered directly to the 
electrophile – creating a flow system identical to the “ideal” written process. 
Developing a process in a flow system offers easier scalability, because scale-up 
can be achieved by using the same equipment adopted for the development phase, and 
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simply letting the system running for a longer time, or by numbering-up multiple systems 
of the same kind operating in parallel14,15. 
The mentioned advantages have attracted to flow chemistry not only academics, 
but also researchers from pharmaceutical agrochemical industries, as processes which 
are safe, efficient, green, cost-effective and have a low footprint are of great appeal16,17. 
Having reproducible access to intermediates and chemical transformations offers 
the possibility of using such single-step processes as units for chemical assembly lines18. 
Single-step modules can be connected together to create a multi-step process, whether 
that is combining synthesis and work-up/purification or stitching together multiple synthetic 
operations in the pursuit of a target molecule. In flow chemistry, when multiple units are 
linked together in a continuous linear setup, it is called a telescoped process9. 
The advantages of such processes are significant, with considerable reduction of 
purification steps, time of synthesis, waste, and manual operations and of course the 
prospect of automating the whole sequence of operations1,4. However, there are several 
limitations that must be considered as well. Due to the continuous addition of reagent 
mixtures via the feed lines, there is a constraint between flow rate, reactor volume and 
residence time: slow reactions require large reactors/low flow rate, whereas fast reactions 
need small reactors/high flow rate (Figure 1.3).  
 
Figure 1.3. Relationship between flow rate, reactor volume and residence time: flow rate is 
dependent on the set values for new feeds and previous steps, and the residence time depends on 
flow rate. Different reactors with different volumes are needed in each step. For every new process 
reactors must be replaced with others of the proper size. 
This constraint entails that a particular multistep process requires a specific 
sequence of reactors with customized volumes determined by the residence times 
necessary for each step. This means that such systems must be reconfigured for every 
new target molecule and physical intervention is required to resize and recombine 
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modules, increasing the arduousness of automating the related processes19. For this 
reason, each telescoped process is typically designed to make one specific molecule, 
meaning that once completed, the entire process must be broken down, redesigned, and 
rebuilt for the next target. Thus, even though the equipment itself is reusable, the 
telescoped linear setups are single purpose, because they are dedicated to the synthesis 
of only one target. 
Byproducts and unused reagents from previous steps are carried through the 
subsequent modules. These can sometimes be removed via inline workups (creating more 
complex processes), otherwise they can have a significant impact on the yield, selectivity, 
or even compromise the achievement of the desired product. The same goes for solvents. 
While prototypes20 and reagent-specific workarounds21 exist, the most common approach 
to telescoped flow reactions is to find a solvent that is compatible with all the different 
transformations to be performed. However, this compromise often means that the chosen 
solvent is not optimal for each transformation, and can negatively impact reaction yield, 
selectivity, and productivity. The general rule of thumb for solvents and reagents in a 
continuous flow synthesis is that once something is added for one step, it is there 
throughout the rest of the process, for better, or more commonly, for worse.  
The more units are linked together, the more complex the system becomes. This 
is true from a hardware perspective (having enough equipment available), an operations 
perspective (more potential points of failure, longer time to reach steady-state22), and a 
chemical perspective (impact of byproducts on the downstream processes, potential 
solubility issues).  
Furthermore, running a multistep process in continuous flow means that every step 
is happening simultaneously, therefore if the same conditions are needed at more than 
one stage of the process the related modules must be repeated (Figure 1.4). Linear 
systems often require multiple heated reactor units, a considerable number of identical 
work-up modules, and a copious number of pumps that increases with the number of 
steps. This redundancy causes the costs of such processes to skyrocket and equipment 





Figure 1.4. Multistep continuous flow processes. Every linear combination is dedicated to one target 
and if the same conditions are required twice in the same process, two identical modules need to 
be repeated.  
1.3 Automated synthesizers - linear vs. iterative processes 
Several efforts have been made to build an automated platform to serve as a 
universal synthesizer which allows for the synthesis of as many targets as traditional 
organic synthesis, with minimum need of manual intervention. Such systems can be 
distributed in two main classes: linear synthesizers, which rely in general on continuous 
flow chemistry, and iterative synthesizers, which are based on solid-phase synthesis. In 
the following sections a brief overview on both approaches will follow, with a focus on their 
application to the automated synthesis of small molecules and the identification of their 
main advantages and disadvantages. 
 Automated platforms based on a linear approach 
Flow systems are immediately suitable for automation as their basic components 
are electronic devices such as pumps, flowmeters, and valves. Another strength of flow 
technology in this respect is its modularity. As described before, flow modules provide 
standardizable access to chemical transformations and can therefore be used as 
interchangeable pieces in a multistep process. Such reconfigurable setups can target 
many different compounds through an indefinite number of combinations of chemical 
reactions, ensuring versatility and enabling the exploration of a wide chemical space.  
On the other hand, reconfiguration of these linear systems based on continuous 
flow is a physical operation that includes disassembly and re-assembly of the relevant 
modules and the automation of such processes is rather challenging. 
Few examples of automated synthesizers exist, based on this linear continuous-
flow approach linking flow chemistry modules in a telescoped manner23,24,25. The effort 
required to automate these machines has generally been justified by the need of platforms 
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for on-demand production of pharmaceuticals as an alternative to the current non-
continuous or “batch” manufacturing. Therefore such systems have focused on the end-
to-end continuous flow synthesis and formulation of active pharmaceutical ingredients 
(API) programmable through software interfaces23. One of the first significant synthesizers 
of this class was developed by researchers from the Massachusetts Institute of 
Technology (MIT) and showed a sequence of modules, which could be used or skipped in 
the synthesis process as needed24. Thus the system is reconfigurable, though the possible 
combinations are limited by the position of the modules and therefore equipment 
redundancy cannot be avoided (Figure 1.5). The capabilities of this on–demand 
reconfigurable synthesizer were showcased by synthesizing four different APIs: 




Figure 1.5. Reconfigurable automated system based on the linear continuous flow approach24. 
Automated synthesizers based on a linear approach have evolved over the past 
decade. The latest version of the MIT system is able to provide access to every module at 
any point of the synthesis through automatic reconfiguration performed by a robotic arm25 
(Figure 1.6). This system has a set of reactors held in a storage location that can be 
selected and inserted into the flow stream using a six-axis robotic manipulator. The same 





Figure 1.6. linear syntheses: an automated, robotic platform for the flow synthesis of organic 
compounds informed by AI planning. Reprinted with permission from reference 25. 
The reagents are connected to the process stack through a dedicated switchboard 
that connects the fluid pumps, outlets, and waste streams to each module as required by 
the chosen chemical process. Two pumps are equipped with selection valves, connected 
with up to twenty-four feedstocks each, thus potentially allowing a wide variety of 
syntheses to be performed. The reaction modules include flow reactors of different 
volumes (100 mL to 3 mL), packed bed reactors (1 to 2 mL) capable of operating at 
temperatures from ambient to 200 °C with pressures up to 17 bar, and a membrane 
separator for liquid–liquid extraction. Fluid connections between adjacent units are 
achieved by vertically stacking them in the required order and a continuous stream of 
reagents is then passed through the sequence.  
The concept was demonstrated by synthesizing six different active pharmaceutical 
ingredients (aspirin, secnidazole, lidocaine, diazepam, (S)-warfarin, and safinamide) and 
two libraries of quinapril and celecoxib derivatives.  
Although way more flexible than the previous one, this upgraded version of the 
modular linear synthesizer still suffers from some of the limitations of continuous flow 
systems. The issue related with the reconfiguration of modules is solved by the 
introduction of the robotic arm, but processes are still happening under continuous flow 
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conditions. This implies that equipment redundancy cannot be circumvented when the 
same conditions are needed more than one time within the same synthesis and that 
parameters like flow rate and concentration are still affected by the values chosen for every 
feed along the process.  
 Automated platforms based on an iterative approach 
Conscious of the limitations of the customized linear approach for small-molecule 
synthesis, particularly when it comes to automation, researchers started considering 
whether generalized processes could be developed for the production of many different 
products using the same manufacturing strategy. For example, solid-phase synthesis 
constitutes an automatable alternative to continuous flow that is particularly well-suited for 
the synthesis of biopolymers such as peptides6, oligonucleotides7, and oligosaccharides8. 
Assembly is accomplished by executing iterative cycles of activation, coupling and 
deprotection steps. Using this strategy monomers are linked together through the same 
type of chemical bond; therefore, the task of the machine is limited to the repetitive 
execution of one type of chemical transformation. The diversity in the final product is given 
by the choice of building blocks and the order of the assembly of the building blocks, which 
are synthesized and functionalized in advance (Figure 1.7). 
 
Figure 1.7. Iterative approach: based on the repetition of iterative cycles of activation, coupling, and 
deprotection steps to attach pre-functionalized monomers to a growing chain. 
Access to synthetic oligomers has been expedited with the introduction of 
automated instruments based on solid-phase synthesis. Given the impact that these 
platforms have made in the related fields, chemists have started investigating whether 
small molecules might be accessed through a similar building-block-based approach. 
Despite their structural diversity, when considering only particular disconnection patterns 
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(e.g. C-C cross-coupling), many types of small molecules can be considered “modular”. 
Additionally, a study of 2014 on the database of U.S. FDA (Food and Drug Administration) 
approved pharmaceuticals highlighted how many small-molecule drugs present some 
degree of redundancy at the fragment level (e.g. 59% of unique small-molecule drugs 
contain a nitrogen heterocycle)26. Such findings suggested that many small molecules can 
be achieved by assembling together common subunits (building blocks) through the 
repetition of one chemical transformation, thus utilizing an iterative synthesis method 
similar to that of the biopolymer synthesizers.  
This concept was demonstrated by Burke et al. synthesizing a broad library of small 
molecules from different classes, using Suzuki-Miyaura couplings to fuse together pre-
functionalized building blocks27. An automated synthesis platform based on this 
technology was developed, employing N-methyliminodiacetic acid (MIDA)-boronate 
building blocks. This synthesizer exploits the features of the trivalent MIDA-ligand which is 
able to tune the reactivity of a boronic acid. The stabilization of boronic acids in the MIDA-
boronate form is reversible, the MIDA-ligand can be removed under aqueous or mild basic 
conditions, releasing the reactive boronic acid. Bifunctional halo MIDA-boronate building 
blocks can be assembled through iterative cycles of cross-coupling and deprotection 
(Figure 1.8).  
 
Figure 1.8. Automated cycle involving deprotection, coupling, and purification steps. Each cycle 
couples a boron-protected haloboronic acid (red sphere) to a growing synthetic intermediate or an 
initial building block (blue sphere). 
This process works in solution-phase; therefore, a purification module must be 
implemented to separate the growing product from the rest of the reaction mixture after 
each cycle. A purification step could be added at the sequence exploiting one unique 
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feature of MIDA-boronates, which have no mobility on silica gel with eluents such as diethyl 
ether and methanol but are instantly released with tetrahydrofuran (THF). This allowed the 
development of a catch-and-release28 purification process for the MIDA-boronate-
containing intermediates that was coupled to their automated iterative assembly. 
This iterative approach is more easily automated than the linear one, but it requires 
multiple off-line operations prior to the automated assembly of the molecules (like the 
synthesis of the properly functionalized building blocks) and the concept itself lacks the 
versatility required to access the structural diversity of organic molecules because each 
synthesizer based on this approach would only be capable of creating one type of chemical 
bond (e.g. C(sp2) - C(sp2) bond).  
1.4 The radial synthesis paradigm 
Once the advantages and disadvantages of both linear and iterative approach to 
automated multistep synthesis are identified, it results evident that the two approaches 
complement each other. Aiming at a universal synthesizer, it is desirable to combine some 
features from both. On one hand, the versatility of modular flow systems is needed to give 
access to chemical diversity. This diversity is unattainable with simple iterative 
approaches, which are only capable of forming a single class of bonds. On the other hand, 
the iterative reutilization of modules in different steps of the same synthesis is crucial to 
escape the limitations of telescoped synthesis previously described; it enables the user to 
select conditions, such as flow rate and residence time, independently from the values set 
for previous steps while avoiding redundancy of equipment. 
The radial synthesis concept is thought to combine the advantages and overcome 
the limitations of linear and iterative approach to multistep synthesis. It is based on a series 
of individually accessible reactors arranged around a central switching station29 (Figure 
1.9). In the radial paradigm, single transformations and multistep sequences are 
performed as sequential, but not simultaneous, series of operations. By decoupling the 
subsequent steps, reactors can be reused under different conditions and residence times 
are independent of any previous step(s). Thus, the amount of equipment required can be 
considerably reduced and reconfigurations of the physical system between synthetic 
processes are avoided. In this way, instead of a multiple-module, single-purpose setup 
(like continuous flow setups) or a single-module, multiple-purpose one (like the iterative 
synthesizers), it is possible to conceive a multiple-module, multiple-purpose instrument 





Figure 1.9. Radial synthesis combines the advantages of the cyclic and the linear approach. Flow 
modules surrounding a central core require minimal equipment while retaining maximum synthetic 
versatility. Reprinted with permission from ref 29 
Several technical challenges need to be addressed to put this concept into practice. 
Solutions must be moved in a radial fashion in a closed system, stable intermediates need 
to be stored, and various flow paths necessary for a wide breadth of synthetic routes have 
to be programmed and controlled. 
Breaking the linearity of continuous flow processes means that reagents cannot be 
pumped continuously, therefore an instrument based on the radial approach must work 
with discrete amounts of solutions. Such liquid segments containing the reaction mixture 
must be pushed by a carrier (a fluid or gas that is inert and not miscible with the reaction 
mixture). This difference from continuous flow systems allows for minimum waste of 
material during process development, though concerns about transferability of such 
processes in continuous flow will have to be addressed.  
1.5 Aim of this thesis  
The aim of this thesis was to develop and validate an automated platform for 
multistep synthesis based on the radial paradigm. Such a prototype was built from 
commercially available parts and was designed in order to require no physical 
reconfiguration between different synthetic processes.  
Thanks to the sequential but non-continuous nature of the steps the same reactor 
can be used at different temperatures within one multistep process. By not performing all 
steps simultaneously, the flow rates for each reaction, that define the reaction times, are 
independent of each other. In this way, long and short residence times can be combined 
in any order without changing the equipment.  
Storing stable intermediates makes both convergent and linear syntheses possible 
and enables the comparison of different synthetic approaches on the same instrument. In 
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addition, concentrations can be screened to accelerate optimizations via inline dilution of 
reagents. A total of twelve different reagents can be stored in the reagent delivery system 
and recombined at will, allowing for the quick generation of compound libraries. In-line 
analysis is possible thanks to the incorporation of different analytical devices (IR and NMR 
spectrometers) which provide feedback on each individual synthetic operation. Thanks to 
its modularity and compatibility with standard flow chemistry setups, the integration of new 
modules within the instrument is straightforward and its capabilities can be rapidly and 
easily implemented. 
This platform is capable of complete flexibility over accessible reaction conditions 
for single or multistep synthesis and is driven by a software that was developed in-house 
upon construction of the hardware and controls all components as an ensemble
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2 The radial synthesizer 
This chapter has been partially modified from: Chatterjee, S.;* Guidi, M.;* 
Seeberger, P. H.; Gilmore, K. Automated Radial Synthesis of Organic Molecules. Nature 
2020, 579, 379–384. DOI: 10.1038/s41586-020-2083-5  
Further permissions related to the material excerpted should be directed to 
Springer Nature. 
* equal authorship 
 
2.1 Design and hardware 
The radial synthesizer (Figure 2.1 and Figure 2.2) is composed of ten valves (seven 
multiposition and three injection valves), connected by perfluoroalkoxy alkanes (PFA) 
tubes and polyether ether ketone (PEEK) fittings and junctions. The system is filled with 
nitrogen gas (used to push and regulate the liquid flow) and pressurized. The stream of N2 
is regulated by three mass flow controllers (MFC, Bronkhorst EL-FLOW Prestige) and the 
pressure is maintained by a digital back pressure regulator (BPR, Bronkhorst EL-PRESS 
P-702CV). All the fluidic connections are made with PFA  tubing (Bola) with an internal 
diameter (ID) 1/32” (0.79 mm) and an outer diameter (OD) 1/16” (1.58 mm). 
PFA was chosen for the wetted parts because of its higher temperature resistance, 
in comparison to fluorinated ethylene propylene (FEP) and its higher transparency when 
compared to polytetrafluoroethylene (PTFE). A gas carrier (N2) was preferred to fluorinated 
oils as inert carrier fluid, due to the latter’s propensity to become miscible with organic 









Figure 2.2. The radial synthesizer is composed of three main blocks: the reagent delivery system 
(RDS), the central switching station (CSS) and the standby module (SM). 
 
In order to avoid ambiguity, all the lines of the system potentially utilized by gas or 
liquid are represented as solid lines. The synthesis pathway lines connect the valves to 
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each other, and each pathway finally leads to a pressurized vessel or the waste container. 
The pressurized gas lines are directly connected to the BPR. Drain lines are connected to 
the waste container that is itself pressurized by a connection to the BPR. All drain lines 
(leading to the waste) are dashed lines, and all lines crossed only by gas are distinguished 
by solid lines featuring the backpressure symbol (Figure 2.3). 
 
Figure 2.3. Legend for the three different types of lines in the synthesizer. All lines are PFA tubes 
ID 1/32”, OD 1/16”.  
All tubing is joined together and connected to valves, reactors, and syringes using 
standard HPLC fittings. Tee junctions and cross junctions are PEEK, PTFE and ETFE 
(ethylene tetrafluoroethylene) (IDEX H&S) (Figure 2.4). A cross junction is used between 
the reagent delivery system and the central station and it is the site where reagents and 
intermediates are mixed. Tee and cross junctions are used to combine all the gas lines 
together converting them to the BPR, and to combine all the drain lines together conveying 
them to the waste container. 
 
Figure 2.4. Tee and cross junctions are used for the connection between lines.  
Three types of valves are utilized in the system: 16 ports and 6 ports multiposition 
valves as well as 6 ports injection (two-position) valves (Figure 2.5). All the valves are 
KNAUER valves of the series AZURA. Multiposition valves have the capability to connect 
one peripheral port at a time to the central one. Two-position valves have the capability to 
connect their ports through two different pathways; one for loading and one for injection. 
 
Figure 2.5. The three types of valves utilized in the synthesizer. 
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Solvents and reagents are stored in homemade pressurized vessels of 5 mL and 
10 mL volumes (Figure 2.6). The vessels are built using PTFE tubes (Bola, OD 12 mm, ID 
10 mm) and they are provided with two outlets (necks) made with reducing unions 1/4 to 
1/16” (from Swagelok) at the top and at the bottom of the vessel.  
 
Figure 2.6. Two-neck pressurized vessel for storage of reagents and solvents. The bottom-neck is 
connected to the Reagents Selector A (section 2.1.2.1) while the top-neck is connected to one of 
the pressurized gas lines. 
Similar vessels were built for the storage of the intermediates generated during 
multistep processes. Those vessels have an additional neck made with a Tee union (1/4”) 
and another reducing union 1/4" to 1/16” (from Swagelok) connected via a PFA tube (OD 
1/16”) to an outlet of the forwarding valve G for the collection of the intermediate (Figure 
2.7).  
A three-neck vessel identical to the one used for the storage of intermediates but 
with a larger volume (30 mL) is used as a pressurized waste container. There are eight 
drain lines in the system (dashed lines in Figure 2.2) that are joined together with tee and 





Figure 2.7. Three-neck pressurized vessel for storage of intermediates. The bottom-neck is 
connected to the Reagents Selector A, the top-neck is connected to one of the pressurized gas 
lines and the side-neck is connected to a line coming from the forwarding valve G. 
Reagent and solvent delivery is accomplished by a syringe pump (Harvard 
Apparatus ELITE infusion/withdrawal) (Figure 2.8) equipped with a gas-tight glass syringe 
(Hamilton, volume 5 mL). 
 
Figure 2.8. Syringe pump infusion/withdrawal are depicted in two variations in the schemes of this 
document, either as a) schematic representation or b) detailed representation. 
The loops are PFA coils of 0.5 mL, the heated reactor is a 20 mL coil connected to 
a heated reactor module (Vapourtec R4)  and the photoreactor is a custom-built 10 mL 




Figure 2.9. The variable temperature reactor connected to the system is represented in three 
different manners within this document a-c). a) General representation of the flow reactor. b) 
representation of the flow reactor when at room temperature. c) Representation of the flow reactor 
when heated. d) The 0.5 mL loop used in both the reagent delivery system and the storage module. 
e) Representation of the flow photoreactor 
The analytics are an in-line IR spectrometer (Mettler Toledo Flow-IR) (Figure 2.10 
a and b) and a benchtop NMR spectrometer (Magritek Spinsolve 40 MHz NMR) (Figure 
2.10 c and d). 
 
 
Figure 2.10. a) Schematic representation of the flow-IR. b) Three-dimensional profile of a multistep 
synthesis passing through the flow-IR (axes: x = wavelength; y = intensity; z = time). c) Schematic 
representation of the flow-NMR. d) Picture of Magritek Spinsolve benchtop NMR. 
The three sections of the radial synthesizer (RDS, CSS, SM) will be described 
separately in detail, with a focus on the function of every component. 
 System compatibilities 
The system proved to be compatible with all common organic solvents and all 
reagents utilized in the current work. The only incompatibility found to date is to triflic 
anhydride, which caused the corrosion of the rotor seal of one valve. After consulting the 
manufacturer (KNAUER) we learned that their rotor seals are made of polyoxymethylene 
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(POM), and can be replaced with components made of different materials when 
specifically needed. All the other parts did not show any weakness neither in the presence 
of strong acids nor bases, showing good performances at high pressure (the system was 
tested up to 8 bar) and temperature (up to 150 °C). 
 Reagent delivery system (RDS) 
Reagent and solvent delivery is accomplished using a set of five valves, two 
syringe pumps and 15 pressurized vessels in which initial reagents and solvents – as well 
as the intermediates formed during the syntheses – can be stored (Figure 2.11). 
 
Figure 2.11. Detail of the reagent delivery system with its components, as well as the length of each 
significant line. The lines that connect the pressurized vessels to the reagent selector A and/or 
solvent selector S are not significant, they are all 50 cm PFA tubes, but their volume is not relevant 
since they are always full of solution once primed. 
2.1.2.1 Reagent and solvent selectors (A and S) 
The reagent selector works in withdrawal and infusion mode: a line connects the 
syringe pump to its central port that can be connected in turn to a single peripheral port at 
a time. Four out of sixteen peripheral ports are dedicated to specific purposes (see below), 
the rest are connected to the homebuilt vessels which contain reagents and solvents. 
 
Special peripheral ports in the reagent selector (A): 
Port 12: Used to load the reagents in the vessels at the beginning of the process 
(before pressurizing the system). Using the syringe pump, the reagents are withdrawn 
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from port 12 and then injected into the desired vessels. Port 12 is then properly sealed 
before the pressurization of the system (Figure 2.12).  
 
Figure 2.12. a) Withdrawal of reagent solution through port 12 in the syringe pump. b) Infusion of 
reagent solution from the syringe pump to the intended vessel. 
Port 16: Drain line to vent out the excess of reagents and solvents during the 
syringe wash and priming cycles. This port is always used when the RDS is in infusion 
mode. 
Port 4: Outlet towards the sample loop selector (B) to fill the loops with the reagent 
solution previously withdrew. This port is always used when the RDS is in infusion mode 
(Figure 2.13). 
 
Figure 2.13. a) Withdrawal of reagent solution from the vessel in the syringe pump. b) Infusion of 
reagent solution from the syringe pump through port 4 towards sample loop selector B. 
Port 15: Connected to a pressurized gas line. This port is necessary because every 
reagent injection towards the sample loops needs to be followed by a certain volume of 
gas (0.4 mL) to clear the common lines (lines a and b in Figure 2.11) before the withdrawal 
of a new reagent. The syringe positioned in the syringe pump is facing down so that the 
gas withdrawn stays above the liquid and cleans the syringe tip and the tubes during the 
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infusion. Thus, every withdrawal of reagents is followed by a 0.4 mL withdrawal of gas 
from port 15 (Figure 2.14 b) and the total volume will be infused through port 4 towards 
the sample loops (Figure 2.14 c).  
 
Figure 2.14. a) Withdrawal of reagent solution from the vessel in the syringe pump. b) Withdrawal 
of 0.4 mL of gas from port 15. c) Infusion of reagent solution and gas from the syringe pump through 
port 4 towards sample loop selector B. 
The remaining 12 ports are all connected to pressurized vessels containing 
reagents solutions and solvents (two-neck vessels as in Figure 2.6) or dedicated to the 
storage of intermediates (three-neck vessels as in Figure 2.7).  
 
Special peripheral ports in the solvent selector (S):  
The solvent selector works in the same way as the reagent selector. Four out of 
six peripheral ports are dedicated to some specific purposes (see below), the remaining 
two are connected to the homebuilt vessels containing solvents. 
Port 3: Used to load the reagents in the vessels at the beginning of the process 
(before pressurizing the system). Using the syringe pump, the solvents are withdrawn from 
port 3 and then injected into the desired vessels. Port 3 is then properly sealed before the 
pressurization of the system (equal to port 12 in reagent selector: Figure 2.12). 
Port 6: Drain line to vent out the excess of reagents and solvents during the syringe 
wash and priming cycles. This port is always used when the RDS is in infusion mode. 
Port 4: Outlet towards the sample loop selector (B) to fill the loops with the reagent 
solution previously withdrawn. This port is always used when the RDS is in infusion mode 
(equal to port 4 in reagent selector: Figure 2.13). 
Port 5: Connected to a pressurized gas line. This port is used to clear the common 
lines (equal to port 15 of the reagents selector: Figure 2.14 b). Thus every withdrawal of 
reagents is followed by a 0.4 mL withdrawal of gas from port 5 and the total volume will be 
infused through port 4 towards the sample loops (equal to port 4 in reagent selector: Figure 
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2.14 c). The reagent and solvent selector work simultaneously at different flow rates which 
are tuned in order to achieve the desired concentrations in the sample loops. 
 
2.1.2.2 Sample loop selector (B) 
The sample loop selector is a six-port multiposition valve that (like the other 
selectors described above) can connect its central port to one peripheral port at a time. It 
receives the combined streams delivered by the syringe pumps of the reagent and solvent 
selector and it diverts the mixture towards the selected sample loop (Figure 2.15). 
 
 
Figure 2.15. Sample loop selector B. In both cases, the reagent solution comes from port 4 of 
reagents selector A. The sample loop selector diverts it to a) port 6 loading sample loop 1 (C); b) 
port 4 loading sample loop 2 (D). 
2.1.2.3 Sample loops (C and D) 
The two sample loops are six-port, injection valves that allow two different flow 
pathways, respectively for loading or injection mode (Figure 2.16). When the sample loop 
is in loading mode, its loop is connected to the inlet line (coming from the sample loop 
selector and containing the reagent solution) and to the drain, allowing the excess solution 
to vent. When the sample loop is in injection mode instead, its loop is connected to the 
MFC (which pushes nitrogen through the loop) and to the outlet line that leads to the CSS. 
The two sample loops are sequentially loaded, and they then switch to injection mode 





Figure 2.16. Two-position injection valve with sample loop. a) Loading mode: inlet port connected 
to the loop, connected to the drain port; MFC connected to the outlet port. b) Injection mode: MFC 
connected to the loop, connected to the outlet port; inlet port connected to the drain port. 
 Central switching station (CSS) 
The two liquid segments coming from the sample loops C and D, pushed by MFC1 
and MFC2, meet each other at a cross junction where they mix and form a liquid segment 
(reaction mixture) whose volume is the combination of the two reagent segments. This 
segment enters the central switching station (Figure 2.17). The components of the central 





Figure 2.17. The central switching station is composed of three 16-port multiposition valves: 
divergent valve E, convergent valve F, and forwarding valve G.  
2.1.3.1 Reaction module 
The reaction mixture slug formed by the meeting of the reagents at the cross 
junction first reaches the divergent valve (E), a 16-port multiposition valve that can connect 
the central port with a single peripheral port at a time. Selection of peripheral ports gives 
access to the different reactors. The divergent valve can host up to 15 different reactors 
(port 16 is connected to a drain line leading to the waste container). The reactors 
connected to the CSS are so far a 20 mL coil reactor connected to a Vapourtec R4 heating 
module that can be used at room temperature (Figure 2.9 b) or heated (Figure 2.9 c) and 
a photoreactor (Figure 2.9 e) that is a 10 mL FEP coil reactor irradiated by a LED lamp 
(420 nm, 72 W) kept at room temperature by immersion in a water bath. 
The reaction mixture flows into the selected reactor for the desired residence time 
and the stream then enters the convergent valve (F), a 16 port multiposition valve that 
collects all the outlet of the different reactors and channels them into a common line that 
passes through a Flow-IR (Figure 2.18) before reaching the forwarding valve (G).To avoid 
confusion, inlet and outlet of the same reactor are connected to ports with the same 
number on the divergent and convergent valves (e.g. the inlet of the heated reactor is 
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Figure 2.18. Divergent valve E and convergent valve F form the reaction module that can divert the 
reaction stream towards different routes dedicated in theory to different chemical transformations 
and then re-converge it into a common path that passes through the flow-IR. 
In the reaction module, a flow-NMR spectrometer is also connected as an 
additional in-line analysis tool. This is not an obligatory stage of the flow path like the flow-
IR (which is positioned across a common line), but must be selected like the reactors. After 
a step is accomplished the crude mixture can be sent to the reagent delivery system by 
the forwarding valve (Figure 2.20 a), mixed with a deuterated solvent (or a solution of 
internal standard if required) and sent to the flow-NMR. In order to allow for enough time 
for the NMR experiment this module can be used in stop-flow conditions (vide infra). 
2.1.3.2 Stop-Flow conditions: 
In order to allow longer residence times into the different modules a “stop-flow” 
capability was implemented that isolates the module in which the step is being performed, 
diverting the nitrogen stream to another one. The desired module is selected at the 
beginning of the step and the liquid segment is sent there, once the liquid segment reaches 
the desired position inside the module, divergent and convergent valves switch to different 
ports sealing the liquid segment. After the desired time for the operation has passed, the 
divergent and convergent valves switch back to the ports connected to the module which 
is holding the liquid segment allowing it to leave and follow the rest of the programmed 




Figure 2.19. Stop-Flow mode: the stream is sent in one module (a) and once the entire liquid 
segment is contained inside that module, valves E and F switch to different ports isolating the 
module for the desired time (b). Once the set time has passed, valves E and F switch back to the 
original ports allowing the liquid segment to leave the module (c). 
2.1.3.3 Forwarding Valve (G) 
After passing through the Flow-IR, the reaction mixture meets the forwarding valve 
(G) (Figure 2.17), another 16-port multiposition valve that directs the reaction solution 
towards the next destination. There are four possible scenarios:  
a) The intermediate formed is to be used later in a convergent multistep synthesis 
(not directly in the following step). The solution is then sent to the RDS and stored in a 
three-neck vessel (Figure 2.20 a) where it will wait to be used in the appropriate step. 
b) The intermediate formed is to be used immediately in the following step (Figure 
2.20 b). The solution is then sent to the standby module.  
c) The final product of the synthesis was formed. The solution is then sent to a 
vessel for the final collection (Figure 2.20 c). 
d) There is also a drain option, to send the reaction mixture to the waste container. 
When the a) three-neck collection vessel in the RDS, b) loop of the standby module 
(H) or c) final collection vessel is full, the step is completed. 
 
Figure 2.20. The forwarding valve G sends the reaction mixture towards the desired destination 
required by the step. a) Storage of the intermediate in the RDS (to be used in a later step). b) 
Storage of the intermediate in the standby module (to be used in the direct following step). c) 
Collection of the final product. 
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 Standby module (SM) 
 
Figure 2.21. Standby module with its two components: the standby loop H and the injection valve 
I. 
The standby module (Figure 2.21) has two components: the standby loop (H) and 
the injection valve (I). The standby loop (H) is a 6-port, injection valve that can allow two 
different flow pathways one for loading and one for injection (same as the sample loops of 
the RDS described in Figure 2.16). The injection valve (I) is a 16-port multiposition valve 
with the function of connecting or disconnecting the standby loop from the cross junction. 
When the connection of H with the cross junction is not needed, i.e. when the loop is being 
loaded (Figure 2.22 a) or when the loop is empty (Figure 2.22 c), the injection valve diverts 
the gas coming from MFC3 to a venting line (port 15). When the intermediate stored in H 
is to be mixed with the new reagents coming from the RDS for a subsequent step, valve 
H is set in injection mode and port 14 is opened on the injection valve I. This connects H 
with the cross junction and creates the scenario of Figure 2.22 b in which three liquid 




Figure 2.22. Standby module in three modes. a) Loop being loaded with the intermediate: H in 
loading mode; I set on venting port 15. b) Intermediate being injected from the loop and meeting 
new reagents coming from RDS for the next step: H in injection mode; I set on port 14 (connected 
to the cross junction). c) Standby module not in use: H can either be in loading or in injection mode; 
I set on venting port 15. 
The injection valve I is also used to regulate the flow rate during the cycles. By 
opening the line that connects it with the CSS, it is possible to exploit the three mass flow 
controllers together, achieving higher flow rates. When the standby loop H is empty but 
the MFC3 is needed to increase the flow rate, the injection valve I can be switched to port 
14 (Figure 2.23 b). It is important to take the precaution of opening the line only after the 
reagents have passed the cross junction (to avoid breaking the reaction mixture slug). 
Similarly, when the standby loop H is being used to mix the intermediate with the 
reagents coming from RDS, but the upcoming cycle requires a low flow rate, it is possible 
to shut down the line right after the injection is complete. This isolates MFC3, diverting its 
stream to the venting port 15 of the injection valve I (Figure 2.23 a) and thus removing its 
contribution to the liquid flow rate in the system. In both scenarios, the position of the 
standby loop valve H (loading or injection) is not important. The time that the system has 
to wait before switching the destination of the injection valve I, in both scenarios described 
above, is referred to as injection time. When it is not necessary to change the destination 





Figure 2.23. Injection valve of the standby module exploited to a) isolate MFC3 and run the steps 
at low flow rates; b) utilize all three mass flow controllers and work at high flow rates. 
2.2 Precipitation handling and prevention of system fouling  
Precipitation in a continuous flow reactor often leads to fouling of the system and 
failure of the process. To avoid system clogging, the radial synthesizer has three ports for 
rapid evacuation of the system in the event precipitation is observed: one at divergent 
valve E (in case precipitation is observed already at the mixing of the reagents), one at 
forwarding valve G (in case precipitation occurs in the reactor), and one at injection valve 
I (in case precipitation takes place in the standby loop H). These evacuation ports are 
connected to an unpressurized vessel. When the evacuation port is opened, a rapid 
depressurization occurs (from the set pressure inside the instrument to ambient pressure), 
causing the liquid slug to rapidly leave the system within one to ten seconds, depending 
on the position of the slug in the synthesizer. The system is then washed with solvents to 






Combinations of the two ways the liquid segments can enter the CSS at the cross 
junction (Figure 2.23 a and b) and the three potential exits from the forwarding valve 
(Figure 2.20 a, b, and c), offer six possible “pathways” the solution can take in the radial 
synthesizer (not including options with regards to the choice of different reactor modules). 
The reagents can enter only from the reagent delivery system (single/1st steps) or from 
both reagent delivery system and standby module (cyclic steps) and the 
intermediate/product can be sent by the forwarding valve to the reagent delivery system 
(RDS), to the standby module (SM), or to a final collection vessel (CV). These 
combinations are reported in Figure 2.24 with the corresponding acronyms. 
 
Figure 2.24. R-R: the reagents enter the CSS only from the RDS and the intermediate is stored in 
the RDS. R-S: the reagents enter the CSS only from the RDS and the intermediate is stored in the 
SM. R-C: the reagents enter the CSS only from the RDS and the intermediate is stored in the CV. 
S-R: the reagents enter the CSS from both RDS and SM and the intermediate is stored in the RDS. 
S-S: the reagents enter the CSS from both RDS and SM and the intermediate is stored in the SM. 
S-C: the reagents enter the CSS from both RDS and SM and the intermediate is stored in the CV.  
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Each pathway has fixed characteristic destinations at the forwarding valve G, 
standby loop H and injection valve I, while the port number of reagent and solvent selectors 
A and S, the port number of divergent and convergent valves (E and F), flow rate, 
temperature and the timings can be changed (Table 2.1 - Table 2.6). These six pathways 
are described in detail below (Figure 2.25 - Figure 2.30).  
Table 2.1. Destination at Forwarding valve G, Standby Loop H, and Injection Valve I during a cycle 
following the R-R pathway. 
 
 Divergent 
Valve (E) a 
Convergent 










… … DRAIN LOAD 15  
Injection 
time 
… … 2 LOAD 15 … 
Cycle time … … 2 LOAD 15 … 
Final 
position 
… … DRAIN LOAD 15  
a variable parameters  
Table 2.2. Destination at Forwarding valve G, Standby Loop H, and Injection Valve I during a cycle 
following the R-S pathway. 
 
 Divergent 
Valve (E) a 
Convergent 










… … DRAIN LOAD 15  
Injection 
time 
… … 15 LOAD 15 … 
Cycle time … … 15 LOAD 15 … 
Final 
position 
… … DRAIN LOAD 15  
a variable parameters 
 
Table 2.3. Destination at Forwarding Valve G, Standby Loop H, and Injection Valve I during a cycle 
following the R-C pathway. 
 
 Divergent 
Valve (E) a 
Convergent 










… … DRAIN LOAD 15  
Injection 
time 
… … DRAIN LOAD 15 … 
Cycle time … … DRAIN LOAD 15 … 
Final 
position 
… … 4 LOAD 15  




Table 2.4. Destination at Forwarding Valve G, Standby Loop H, and Injection Valve I during a cycle 
following the S-R pathway. 
 
 Divergent 
Valve (E) a 
Convergent 










… … DRAIN LOAD 15  
Injection 
time 
… … 2 INJECT 14 … 
Cycle time … … 2 LOAD 15 … 
Final 
position 
… … DRAIN LOAD 15  
a variable parameters 
Table 2.5. Destination at Forwarding Valve G, Standby Loop H, and Injection Valve I during a cycle 
following the S-S pathway. 
 
 Divergent 
Valve (E) a 
Convergent 










… … DRAIN LOAD 15  
Injection 
time 
… … 15 INJECT 14 … 
Cycle time … … 15 LOAD 15 … 
Final 
position 
… … DRAIN LOAD 15  
a variable parameters 
Table 2.6. Destination at Forwarding Valve G, Standby Loop H, and Injection Valve I during a cycle 



















DRAIN INJECT 14 … 
Cycle time … … 
 





4 LOAD 15  






Figure 2.25. Pathway R-R: reagents coming only from the RDS and the generated intermediate is 






Figure 2.26. Pathway R-S: reagents coming only from the RDS and the generated intermediate is 
stored in the standby loop. Grayed-out sections are not utilized in this pathway. 
 




Figure 2.27. Pathway R-C: reagents coming only from the RDS and the generated product is 





Pathway S-R:  
 
Figure 2.28. Pathway S-R: reagents coming from both RDS and SM and the generated intermediate 





Pathway S-S:  
 
Figure 2.29. Pathway S-S: reagents coming from both RDS and SM and the generated intermediate 




Pathway S-C:  
 
Figure 2.30. Pathway S-C: reagents coming from both RDS and SM and the generated product is 






 Calibration of solvent and reagent selectors 
Calibration tests were run to establish the reliability of the dilution capability of the 
reagent delivery system. In order to do that, a 1 M solution of 1,3,5-trimethoxy benzene in 
CDCl3 was loaded in the solvent pool, a 1 M solution of 1,2,4,5-tetramethyl benzene in 
CDCl3 was loaded into the reagent pool and a series of data was collected varying the 
infusion rate of both syringe pumps to achieve various concentrations in the sample loops. 
The final concentrations were analyzed using the flow-NMR spectrometer in stop-
flow mode: after the loops were loaded with the desired ratio of both solutions, port 15 of 
both divergent and convergent valves (connected to inlet and outlet of flow-NMR) were 
selected. Once the NMR flow cell was entirely filled with the freshly generated solution, 
port 2 of both divergent and convergent valves (connected to a 0.1 mL PFA tube) were 
selected diverting the stream towards an alternative line and leaving to the instrument 
enough time for the NMR experiment. After that time, both port 15s were reselected and 
the mixture was sent to collection. 
Measurements of the same solutions with 400 MHz Bruker NMR spectrometer 
were consistent with the data of the flow-NMR. These tests were repeated 3 times and 
provided comparable results (Figure 2.31). 
 
Figure 2.31. 1H NMR spectra were recorded with the flow-NMR for different ratios of trimethoxy 
benzene and tetramethyl benzene generated by playing with different infuse rates of the syringe 
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pumps of reagent and solvent selectors. These tests were repeated three times giving comparable 
results. 
 Calibration of flow rate: 
Since gas and liquid have different compressibility and every solvent has a different 
viscosity and a different expansion behavior when heated, calibration of the dependence 
of flow rate from the type of solvent and temperature was necessary to predict the 
residence time of our steps. The solvents I used for my studies were water, acetonitrile, 
and methanol. The observed liquid flow rate for these solvents reported in Table 2.7 and 
Figure 2.32 - Figure 2.39. I distinguished between two types of timings: a) residence time 
– the actual time that the reaction spends inside the reactor and b) cycle time – the overall 
time of each step (time that the reaction slug takes to go from the beginning to the end of 
its path).  For the residence time, the time which the head of the reaction slug takes to go 
from the beginning to the end of the reactor was measured at different set flow rates and 
temperatures for the three different solvents. The flow rate was calculated as a function of 
the residence time and reactor volume (10 mL). Every test was performed in duplicate. 
While the residence time at the same conditions sometimes varied a couple of seconds, 
the resulting flow rates were reproducible. 
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Table 2.7. The observed liquid flow rate is dependent on temperature, solvent, and set gas flow 
rate during the residence time. Every test was made at 5 bar and was repeated twice. 
Solvent T °C V (mL) 
Set Gas Flow Rate 
(mL/min) 
Time (s) 
Resulting Liquid Flow Rate 
(mL/min) 




































































Figure 2.32. : Plot of the actual flow rate of a 1 mL methanol slug as a function of the temperature 
when pressure is 5 bar and the set gas flow rate is 9 mL/min. 
 






































Figure 2.33. Plot of the actual flow rate of a 1 mL water slug as a function of the temperature when 
pressure is 5 bar and the set gas flow rate is 9 mL/min. 
 
 
Figure 2.34. Plot of the actual flow rate of a 1 mL acetonitrile slug as a function of the temperature 
when pressure is 5 bar and the set gas flow rate is 9 mL/min. 
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Figure 2.35. Plot of the actual flow rate of a 1 mL methanol slug as a function of the temperature 
when pressure is 5 bar and the set gas flow rate is 3 mL/min. 
 
 
Figure 2.36. Plot of the actual flow rate of a 1 mL methanol slug as a function of the set gas flow 
rate when pressure is 5 bar and temperature is 23 °C. 
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Figure 2.37. Plot of the actual flow rate of a 1 mL methanol slug as a function of the set gas flow 
rate when pressure is 5 bar and temperature is 60 °C. 
 
Figure 2.38. Plot of the actual flow rate of a 1 mL acetonitrile slug as a function of the temperature 
when pressure is 5 bar and the set gas flow rate is 9 mL/min (blue) and 3 mL/min (orange). 
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y = 0,0044x + 1,5167
R² = 0,999






































Figure 2.39. Plot of the residence time of a 1 mL slug of methanol, acetonitrile, and water as a 
function of the temperature when pressure is 5 bar and set gas flow rate is 9 mL/min. 
During the cycle time, the liquid slug passes from an unheated area (from valves 
C and D to valve E), through the heated reactor (from valve E to valve F), to an unheated 
section again (valve F through flow-IR and valve G towards either H or RDS or final 
collection). The cycle times measured for the three solvents at different T are provided in 
Table 2.8 and Figure 2.40 - Figure 2.42 for the different solvents used. 
 
Table 2.8. The observed liquid flow rate during the course of the entire cycle is dependent on the 
temperature, solvent and set gas flow rate. Every test was made at 5 bar and was repeated twice.  
Solvent T °C 
V 
(mL) 




Resulting Liquid Flow 
Rate (mL/min) 















































































Figure 2.40. Plot of the actual flow rate of a 1 mL slug of methanol as a function of the temperature 
during the cycle time (blue) and during the residence time (orange). Pressure 5 bar, set gas flow 
rate 9 mL/min. 
 
 
Figure 2.41. Plot of the actual flow rate of a 1 mL slug of water as a function of the temperature 
during the cycle time (blue) and during the residence time (orange). Pressure 5 bar, set gas flow 
rate 9 mL/min. 
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R² = 0,9989
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Figure 2.42. Plot of the actual flow rate of a 1 mL slug of acetonitrile as a function of the temperature 
during the cycle time (blue) and during the residence time (orange). Pressure 5 bar, set gas flow 
rate 9 mL/min. 
The cycle time is different for the different pathways, and the degree of precision 
needed on each of them is also variable. The pathways ending in the RDS have as final 
destination from forwarding valve (G) the corresponding outlet port that delivers the 
solution to the three-neck vessel. When this is the case, the collection will continue until 
the beginning of the next step. As such, it is sufficient to give as a cycle time a value that 
is slightly longer than the predicted one (10 seconds to 1 minute depending on the chosen 
flow rate) to ensure that the entire solution will be collected. 
There is also room for error with pathways ending in the collection vessel. For 
processes where the collection takes place in a pressurized vessel, the forwarding valve 
will be set to its final destination from the beginning of the step. Again, here it is sufficient 
to set a value for the cycle time that is slightly longer than the predicted one to ensure that 
the entire solution will be collected. Since the mass flow controllers do not stop the gas 
flow upon cycle end, the collection will continue until the operator manually stops the 
instrument. 
In the instance where the collection takes place in an unpressurized vessel, the 
forwarding valve will switch to the unpressurized port right after the intended residence 
time is over and the collection will take place in the time in which the system depressurizes, 
and will continue until the operator manually switches off the mass flow controllers. 
For pathways ending in the standby module, the accuracy of the cycle time is more 
important. The final destination of the forwarding valve is the drain port that diverts the gas 
stream from the line that feeds the standby loop, thus stopping the liquid slug there. In 
such cases, it is necessary that G feeds the loop for the time needed to fill it and switches 
to the drain port when the middle of the slug is held in the standby loop H. An error of few 
seconds is tolerated but by changing the solvent mixture and the temperature, the cycle 
y = 0,0032x + 1,5456
R² = 0,9994
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time may potentially vary by dozens of seconds (Figure 2.39). I considered it appropriate 
to time each step during the optimization phase (stopping it manually) in order to have 
empirical time values which will then be typed in the appropriate fields during the 
preparation of the automated sequence. As soon as the right timings are found, each step 
can be run autonomously, as under the same conditions, flow rate and the corresponding 
residence and cycle times, are fully reproducible. 
Every synthetic step optimized in the following chapter (chapter 0), therefore, was 
first run “manually”, stopping the flow when the reaction mixture reached the desired point 
(by manually selecting the proper destination of each valve). The related timings were then 
integrated into automated sequences.  
2.5 Software  
The control software, written in LabVIEW, relies on a hierarchy of five layers of 
virtual instruments. At the graphical user interface31, which is remotely accessible (the 
highest level), users enter information relating to the reagents delivery, pathway (section 
2.3 of this document), reaction conditions, and destination to achieve a multistep process, 
a set of single-step reactions, or a combination thereof. Beneath the interface, a series of 
virtual instruments (VIs) control and interface the hard- and software. These VIs are timed 
to render the instrument fully autonomous. 
Details about the software will not be included in this thesis because it was 
developed by my colleague: Dr. Sourav Chatterjee. Further information can be found in 








3 Proof of concept 
This chapter has been partially modified from: Chatterjee, S.;* Guidi, M.;* 
Seeberger, P. H.; Gilmore, K. Automated Radial Synthesis of Organic Molecules. Nature 
2020, 579, 379–384. DOI: 10.1038/s41586-020-2083-5  
Further permissions related to the material excerpted should be directed to 
Springer Nature. 
* equal authorship 
 
The last section of this chapter (3.4) has been adapted from: Guidi, M.; Moon, S.; 
Anghileri, L.; Cambié, D.; Seeberger, P. H.; Gilmore, K. Combining Radial and Continuous 
Flow Synthesis to Optimize and Scale-up the Production of Medicines. Submitted. 
 
The processes for the validation of the radial synthesizer were chosen in order to 
demonstrate the capabilities of the instrument. 
3.1 Convergent vs linear syntheses  
The radial synthesizer can accommodate different synthetic strategies without 
instrument reconfiguration. In order to showcase this feature, I selected the synthesis of 
the anticonvulsant drug rufinamide that can be achieved through both linear and 
convergent approaches32 (Scheme 3.1).  
 
Scheme 3.1. Convergent (top) vs linear (bottom) synthesis of rufinamide. 
These two processes would require two different setups if performed under 
continuous flow conditions and the repetition of similar, if not equivalent, pieces of 
equipment in different synthetic steps within the same process. Reutilization of the same 
modules, when switching from one synthesis to the other, is possible but a full disassembly 
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and reassembly of the setup is needed to reorganize the order of reactors and feeds 
(Figure 3.1). 
 
Figure 3.1. Convergent vs linear synthesis of rufinamide performed under continuous flow 
conditions. Recombination of equipment, as well as repetition of identical modules, are needed. 
The radial synthesizer instead could switch between the two routes and perform 
the optimization of both via proper selection of the order of addition of reagents and 
destinations of the multiport valves. Reutilization of the same reactor within one radial 
process was possible to such an extent that all the synthetic steps shown in this section 




Figure 3.2. Rufinamide (5) was synthesized via convergent (top; R–R, R–S, S–C) and linear 
(bottom; R–S, S–S, S–C) processes using the same instrument without reconfiguration. 
The two synthetic approaches to rufinamide could be performed starting from the same 
reagent solutions as inline dilution with different solvents are possible (section 2.1.2). The 
reagent delivery system was loaded with five solutions and two wash solvents in the 
reagent selector (Figure 3.3) and two solvents for dilution in the solvent selector (Vessel 








Vessel 1: empty (used for storage of intermediate 2 in the conver-
gent synthesis) 
Vessel 2: 2,6-difluorobenzyl bromide (1), 1.5 M in CH3CN:MeOH 
= 1:4 
Vessel 3: empty 
Vessel 5: sodium azide, 1.6 M in H2O:MeOH = 3.5:6.5 
Vessel 6: empty 
Vessel 7: methyl propiolate (3), 2 M in CH3CN 
Vessel 8: empty 
Vessel 9: NH3, 7.5 M in H2O  
Vessel 10: CuI, 0.0375 M in CH3CN 
Vessel 11: empty 
Vessel 13: CH3CN  
Vessel 14: H2O  
Figure 3.3. Five reagents were used for both routes. White vessels were left empty and grey dots 
represent ports which are dedicated to other purposes other than connecting the reagent selector 
to the reagent vessels (see section 2.1.2.1). 
Each reaction was initially optimized individually in the synthesizer by screening 
solvents, stoichiometry, concentration, temperature, and residence time. For individual 
optimization, the R-C pathway was employed, conversion was monitored inline by Flow-
IR and yield was determined by offline analysis of collected samples. Then steps were 
coupled together in a convergent or a linear manner and the resulting multistep sequences 
were optimized in order to maximize overall yield and quality of the product. 
 Radial convergent synthesis of rufinamide 
The following acronyms are used to refer to the individual reactions in the 
convergent process: Step 1 = C1, Step 2 = C2, Step 3 = C3 (Scheme 3.2).  
 
Scheme 3.2. Convergent synthesis of rufinamide 5 (C1 + C2 + C3), where either intermediate 2 or 
4 is stored in the reagent delivery system for use in the final step (C3). 
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3.1.1.1 Individual optimization of C1  
 
Scheme 3.3. Synthesis of 2,6-difluorobenzylazide 2 (C1) from 2,6-difluorobenzyl bromide and 
sodium azide. 
A preliminary offline solvent screening was performed to identify solvents that fully 
solubilize the respective reagents. 2,6-Difluorobenzyl bromide (1) was found to have good 
solubility in CH3CN and NaN3 in H2O. Two solutions of 1 (0.82 M and 1.64 M in CH3CN) 
and two solutions of NaN3 (0.98 M, 1.97 M in H2O) were prepared and loaded into separate 
vessels in the reagent selector (Figure 3.3).  
Initially, the effects of concentration, temperature, and residence time on the 
conversion of 1 were screened using the pathway R-C in the synthesizer (Figure 2.27). 
Upon collection, the solution was analyzed by 19F NMR following the addition of 1 drop of 
deuterated DMSO to the NMR tube. Intermediate 2 was never isolated (except for 
characterization). The results of these experiments are reported in Table 3.1. 
Table 3.1. Conditions screening for step C1.a 
Entry Conc. 1 (M) 
 
NaN3 equiv. T (°C) t (min) Conv. %b 
1 0.82 
 
1.2 70 10c 79 
2 0.82 
 
1.2 70 20d 82 
3 0.82 
 
1.2 100 10c 85 
4 0.82 
 
1.2 100 20d >95 
5 1.64 
 
1.2 100 20d >95 
a Conditions screened using the Pathway R-C pathway on the synthesizer; 1 solubilized in CH3CN, 
2 in H2O; back pressure 5 bar. The reaction was monitored via Flow-IR following the formation of 
the peak at 2090 cm-1. b Conversion determined by the ratio of the integrated area of 2 to the total 
area for peaks 1 + 2 in 19F NMR. c Set gas flow rates: MFC1 = MFC2 = 4 ml/min. d Set gas flow 
rates: MFC1 = MFC2 = 2 mL/min. 
 
Despite clean and full conversion to the desired 2,6-difluorobenzyl azide (2), the 
reaction mixture was biphasic. This was observed both within the synthesizer during the 
reaction and in the collection vessel. Aiming at storing intermediate 2 within the RDS I had 
to find a way to avoid phase separation that could compromise the correct delivery of 2 in 
future steps. Methanol prevented phase separation. Unfortunately, neither reagent 1 nor 
sodium azide were soluble in pure methanol, however, methanol was found to be an 
effective co-solvent for both reagents. Based on the findings in Table 3.1, different solvent 
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ratios, stoichiometries, concentrations, temperatures, and residence times were screened 
using the R-C pathway (Table 3.2). The final optimized conditions are those shown in entry 
5. 




















H2O     (50) 
100 25c >95 2 




H2O     (50) 
100 25c >95 2 




H2O     (35) 
100 25c >95 1 




H2O     (35) 
40 25c >95 1 









a Conditions screened using the R-C pathway on the synthesizer; back pressure 5 bar. The reaction 
was monitored via Flow-IR following the formation of the peak at 2090 cm-1. b Conversion 
determined by the ratio of the integrated area of 2 to the total area for peaks 1 + 2 in 19F NMR. NMR 
yield for entry 5 vs trifluorotoluene as internal standard is given in parenthesis. c Set gas flow rates: 
MFC1 = MFC2 = 2 mL/min. d Set gas flow rates: MFC1 = MFC2 = 9 ml/min. 
 
3.1.1.2 Individual optimization of C2 
 
Scheme 3.4. Synthesis of propiolamide 4 (C2) via amidation of methyl propiolate (3) with aqueous 
ammonia. 
A preliminary offline solvent screening was performed to identify solvents that 
solubilize the respective reagents. Methyl propiolate (3) is a liquid not miscible with water, 
but it is miscible with acetonitrile. Solutions of different concentration of 3 (1 M, 2 M, 2.36 
M, 4 M) in acetonitrile were prepared and loaded in the reagent selector, along with a 7.5 
M solution of aqueous ammonia. The amidation was then performed using the R-C path 
(Figure 2.27) on the synthesizer, varying stoichiometry, and residence times. Following 
collection, the crude mixture was collected, evaporated using a rotavap (to remove NH3 
and CH3CN) and analyzed via 1H NMR and 13C NMR in deuterated methanol (CD3OD). 
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Table 3.3. Condition screening for step C2.a 
Entry 
 
Conc. 3 (M) t (min) Conv. %b 
1 
 










a Conditions screened using the R-C pathway on the synthesizer; all tests performed at room 
temperature, back pressure 5 bar. The reaction was monitored via Flow-IR following the formation 
of the peaks at 1670 and 1100 cm-1. b Conversion determined by the ratio of the integrated area of 
4 (proton bond to the sp carbon) to the total area for peaks of 3 + 4 in 1H NMR and 13C NMR. c Set 
gas flow rates: MFC1 = MFC2 = 9 ml/min. d Set gas flow rates: MFC1 = MFC2 = 4.5 ml/min. 
 
3.1.1.3 Individual optimization of C3 
 
Scheme 3.5. Synthesis of rufinamide (5) via a copper-catalyzed Huisgen cycloaddition of 2,6-
difluorobenzyl azide (2) and propiol amide (4). 
The solubility of copper catalysts in different solvents and concentrations was first 
determined offline. The results are shown in Table 3.4. Entry 1, 2, 9, and 15 of Table 3.4 
were then loaded into the RDS along with the previously made solution of intermediate 2 
at two different concentrations (0.75 M and 0.375 M). The reactivity of the different 
catalysts for C3 was then screened as part of a two-step sequence (R-S, S-C), with 
intermediate 4 freshly made and stored in the standby loop each time (reaction conditions 
Table 3.3, entry 4, conc. 1 M). 
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Table 3.4. Solubility tests for copper catalyst.a 
Entry Catalyst System Solvent Concentrationb Solubility 
1 
CuSO4:Sodium Ascorbate = 1:2 
H2O 
5% (37.5 mM) Soluble 
2 10% (75 mM) Soluble 
3 
CH3CN 
5% (37.5 mM) Insoluble 
4 10% (75 mM) Insoluble 
5 
MeOH 
5% (37.5 mM) Insoluble 




5% (37.5 mM) Insoluble 
8 10% (75 mM) Insoluble 
9 
CH3CN 
5% (37.5 mM) Fine suspensionc 
10 10% (75 mM) Insoluble 
11 
MeOH 
5% (37.5 mM) Insoluble 




5% (37.5 mM) Insoluble 
14 10% (75 mM) Insoluble 
15 
CH3CN 
5% (37.5 mM) Soluble 
16 10% (75 mM) Insoluble 
17 
MeOH 
5% (37.5 mM) Insoluble 
18 10% (75 mM) Insoluble 
a Solubility tests were performed in open test tubes. b Concentrations are of the copper species (if 
fully soluble); the percentage refers to the molar concentration with respect to 2 (0.75 M) in C3. c 
CuAc is not completely soluble in any of the tested solvents but in acetonitrile it forms a very fine 
suspension that could be used in flow without clogging. 
 
Compatibility between these solutions was evaluated beside other reaction 
conditions in a series of tests carried out using the S-C pathway on the synthesizer. 
Screened parameters and results are shown in Table 3.5. The optimal conditions were 
determined to be entries 5 and 6. 
Table 3.5: Conditions scouting for step C3.a 
Entry 
 
Conc. 2 (M) Catalyst t (min)b Precipitation Conv. %e 
1 
 
0.75 CuSO4 10% in H2O - c at mixing stationc 0 
2 
 
0.75 CuSO4 5% in H2O - c at mixing stationc 0 
3 
 
0.75 CuAc 5% in CH3CNe 4d in reactord >95 
4 
 
0.75 CuI 5% in CH3CN 4d in reactord >95 
5 
 
0.75 CuI 5% in CH3CN 4 upon collectiond >95 (88) 
6 
 
0.375 CuI 5% in CH3CN 4 not observedd >95 
a Conditions screened using the S-C pathway on the synthesizer; 4 was made according to the 
procedure described in entry 4 of Table 3.3 and stored in the standby module; all tests are 
performed at room temperature; back pressure 5 bar. The reaction was monitored via Flow-IR, 
following the formation of the peaks at 1640, 1500 and 1080 cm-1. b Set gas flow rates: MFC1 = 
MFC2 = 4.5 ml/min; when precipitation was observed the reaction mixture was expelled as 
described in section 2.2. c Sodium ascorbate precipitates as soon as it comes into contact with the 
other solutions (at the mixing station) with consequent inactivation of the catalyst. The mixture was 
expelled using the unpressurized exit of the divergent valve E. These reactions were allowed to 
continue after collection, stirring for 10 minutes but they showed no conversion d Rufinamide 
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precipitation occurred in the reactor 4 minutes after mixing. The mixture was expelled using the 
unpressurized exit of the forwarding valve G. d CuAc solubility is as good as reported in Table 3.4 
entry 9, the test was possible because the particles were small enough to avoid clogging at the 
beginning of the process and went into solution once diluted with the other solutions (at the mixing 
station). e Conversion determined after drying the crude for 30 minutes and analyzing it via 1H, 13C, 
19F NMR in DMSO-d6; NMR calculated yield vs. 1,3,5-trimethoxybenzene as internal standard is 
given in parenthesis for entry 5. 
 
3.1.1.4 Final process optimization 
Optimal conditions for the three steps were identified: C1: (Table 3.2, entry 5), C2: 
(Table 3.3, entries 2, 3, 4) C3: Table 3.5, entries 5 and 6. The optimal set of overall 
conditions were then selected from these options. The convergent synthesis uses the 
combination of pathways R-R, R-S, S-C. As such, the best process was: 
C1: (R-R), Table 3.2 entry 5  
C2: (R-S), Table 3.3 entry 3 
C3: (S-C), Table 3.5 entry 5  
 
The system was then pressurized to 5 bar and the following protocol was applied 
(Figure 3.4 and Figure 3.5 - Figure 3.7). 
 
 
Figure 3.4. Pathways and conditions for the three steps (C1, C2 and C3) of the convergent 





C1 (Figure 3.5):  
 Reagents withdrawn from vessel 2 (1) and vessel 5 (NaN3). 
 R-R pathway: product sent through port 2 of forwarding valve to vessel 1 
(intermediate 2 stored in the RDS). 
 Temperature of heated reactor: 40 °C. 
 Back pressure: 5 bar. 
 Gas flow rate set: MFC 1 = MFC 2 = 9 mL/min. 
 Effective liquid flow rate: from each sample loop, 1.8 mL/min. Total liquid 
flow rate = 3.6 mL/min. 
 Injection time: 0 s. 
 Cycle time: 460 s (7 min 40 s). 
 Residence time in the heated reactor: 5 min 30s. 
Table 3.6: Destination at all valves for step C1 
 Divergent 
Valve (E) a 
Convergent 










14 14 DRAIN LOAD 15  
Injection 
time 
14 14 2 LOAD 15 0 
Cycle time 14 14 2 LOAD 15 460 
Final 
position 





Figure 3.5. First step (C1) of the radial convergent synthesis of rufinamide (R-R), with storage of 
intermediate 2 in the RDS. Bold lines indicate the solution path. Starting materials are reported in 





C2 (Figure 3.6):  
 Reagents withdrawn from vessel 7 (3) and vessel 9 (NH3(aq)). 
 R-S pathway: reagents coming from RDS, product sent through port 15 of 
forwarding valve towards the standby loop (intermediate 4 stored in the 
standby module). 
 Temperature of reactor: room temperature. 
 Back pressure: 5 bar. 
 Gas flow rate set: MFC1 = MFC2 = 4.5 mL/min. 
 Actual liquid flow rates: from each sample loop, 0.9 mL/min. Total liquid flow 
rate = 1.8 mL/min. 
 Injection time: 0 s. 
 Cycle time: 775 s (12 min 55 s). 
 Residence time in the heated reactor: 11 min. 
Table 3.7. Destination at all valves for step C2 
 Divergent 
Valve (E) a 
Convergent 










14 14 DRAIN LOAD 15  
Injection 
time 
14 14 15 LOAD 15 0 
Cycle time 14 14 15 LOAD 15 775 
Final 
position 





Figure 3.6. Second step (C2) of the radial convergent synthesis of rufinamide (R-S), with storage 
of the intermediate 4 in the standby module. Bold lines indicate the solution path. Starting materials 





C3 (Figure 3.7):  
 Reagents withdrawn from vessel 1 (2) and vessel 10 (CuI). 
 S-C pathway: reagents coming from both RDS and Standby module, 
product sent through port 14 of forwarding valve towards a pressurized 
collecting vial. 
 Temperature of reactor: Room temperature. 
 Back pressure: 5 bar. 
 Gas flow rate set: MFC1 + MFC2 + MFC3 = 9 mL/min. 
 Actual liquid flow rate: from each sample loop and standby loop, 1.8 
mL/min. Total liquid flow rate = 5.4 mL/min. 
 Injection time: 0 s. 
 Cycle time: 180 s (3 min 50 s). 
 Residence time: (3 min 42 s). 



















DRAIN INJECT 14 0 
Cycle time 14 14 
 










Figure 3.7. The third step (C3) of the radial convergent synthesis of rufinamide (S-C). Bold lines 
indicate the solution path. Starting materials are reported in blue and products in red. 
 
The concentration of the final mixture is 0.25 M, at this concentration the 
precipitation of rufinamide starts after only 4 minutes from the meeting of reagents. It is 
therefore very important to expel the mixture from the system within 4 minutes in order to 
avoid clogging. The crude was stirred for 15 minutes at room temperature and the crystals 
of rufinamide were then filtered, washed two times with demineralized water, dried under 
vacuum, and analyzed via 1H NMR. The 1H NMR yield versus 1,3,5-trimethoxybenzene as 




 Radial linear synthesis of rufinamide 
Like for the convergent synthesis, also for the linear one each step of the linear 
sequence was individually optimized and then linked with the others for the optimization 
of the final process. The following acronyms are used to refer to the individual reactions in 
the linear process: Step 1 = L1, Step 2 = L2, Step 3 = L3 (Scheme 3.6). 
 
Scheme 3.6. Linear synthesis of rufinamide 5: L1 + L2 + L3. 
3.1.2.1 Individual optimization of L1  
The first step of the linear synthesis is similar to the convergent synthesis C1 
(Scheme 3.3), with the only difference being that in this process intermediate 2 will be 
stored in the standby loop instead of the RDS. Due to the low solubility observed for 
rufinamide in the convergent process, lower concentrations of 1 were explored in order to 
prevent potential precipitation of the cycloadduct 6 in the subsequent step L2. 
A concise screening was carried out varying concentration of the initial solution of 
1 (Table 3.9) from the conditions previously optimized for C1 (Table 3.2, entry 5). The 
reaction performs equally well in all conditions screened. 
Table 3.9. New concentrations screened for step L1.a 
Entry 
 
Conc. 1 (M) Conc. NaN3 (M) Conv. %b 
1 
 
1.5 1.57 >95% 
2 
 
1.0 1.05 >95% 
3 
 
0.75 0.79 >95% 
a Conditions screened using R-C pathway (Figure 2.27) on the synthesizer; 1 solubilized in 
CH3CN:MeOH = 1:4, 2 in H2O:MeOH = 3.5:6.5 (1.2 equiv.); reactor temperature 40 °C; residence 
time 5 minutes; back pressure 5 bar; set gas flow rates: MFC1, MFC2 = 9 ml/min. The reaction was 
monitored via Flow-IR following the formation of the peak at 2090 cm-1. b Conversion determined 
by the ratio of the integrated area of 2 to the total area for peaks 1 + 2 in 19F NMR in CDCl3.  
 
3.1.2.2 Individual optimization of L2 
 
Scheme 3.7. Formation of cycloadduct 6 via a copper(I)-catalyzed Huisgen cycloaddition (L2). 
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The conditions for this step, also a Huisgen cycloaddition, are similar to what was 
already optimized for C3 (Scheme 3.5). Differences in reactivity of 3 (step L2) and 4 (step 
C3) were taken into consideration, as well as the solubility of the formed intermediate (6), 
which must be temporarily stored in the standby loop prior to L3. The step was optimized 
as part of a two-step process (L1 + L2), similar to how C3 was optimized. 
Starting from the conditions optimized in C3, a 1 M solution of methyl propiolate 3 
and three solutions with different concentrations of CuI in CH3CN (0.0375 M, 0.025 M, 
0.0188 M) were loaded in the RDS. Their reactivity was tested with freshly made 
intermediate 2 (as in entries 1, 2 and 3 of Table 3.9) and stored in the standby loop each 
time. A series of tests were carried out using the S-C pathway (Figure 2.30), following the 
synthesis of 2 using the R-S pathway (Figure 2.26) on the synthesizer, to screen 
concentrations, stoichiometries, temperature, and reaction time (Table 3.10). 
Table 3.10. Condition screening for step L2.a 
Entry 
 
Conc. 2 (M) Conc. CuI (M) T (°C) Precipitationc t b Conv.%f 
1 
 
0.75 0.0375 25 - 15 min 33 
2 
 
0.75 0.0375 25 After 30 min 45 mind 77 
3 
 
0.75 0.0375 25 After 30 min 1 hd 91 
4 
 
0.75 0.0375 40 After 6 min 6 mine 51 
5 
 
0.5 0.025 40 After 30 min 20 min 49 
6 
 
0.5 0.025 60 After 30 min 20 min >95 
7 
 
0.375 0.0188 60 - 20 min >95 
a Conditions screened using the S-C path on the synthesizer; 3 was 1 M in CH3CN; CuI dissolved 
in CH3CN; back pressure 5 bar. The reaction was monitored via Flow-IR following the 
disappearance of peak at 2090 cm-1 and the formation of peak at 1722 cm-1. b MFC1 = MFC2 = 
MFC3 = 4 ml/min. Stop-flow conditions applied for residence times longer than 12 min 30 s. c When 
precipitation was observed, the reaction mixture was expelled (see general information) from the 
unpressurized port of the forwarding valve G. d Due to precipitation, I was forced to expel the 
reaction mixture from the synthesizer before the indicated reaction time, the reaction continued in 
a vial and was sampled and analyzed after the reported time. e Due to precipitation, I was forced to 
expel the reaction mixture from the synthesizer and it was analyzed immediately. f Conversion 
determined by the ratio of the integrated area of 6 to the total area for peaks 2 + 6 via 19F NMR and 
1H NMR (following the disappearance of the benzylic peaks of 2 in favor of those of 6) in DMSO-
d6. 
 
Intermediate 6 was also crystallized, adding few drops of demineralized water to 
the crude mixture coming from entry 6 of Table 3.10 and stirring for 4 hours. The crystals 




3.1.2.3 Individual optimization L3  
 
Scheme 3.8. Synthesis of rufinamide 5 via amidation of 6 using aqueous ammonia (L3). 
Similar to C2, this step involves the formation of an amide bond from a methyl ester 
and aqueous ammonia. However, transfer of the identical conditions previously optimized 
(room temperature, 10 minutes, Table 3.3, entry 2, 3, 4) was not possible, with a ten 
minutes residence time at room temperature giving no conversion (Table 3.11, entry 1). 
As such, a screening of higher temperatures and longer residence times was performed. 
A 7.5 M ammonia solution in H2O was reacted with intermediate 6 (0.25 M or 0.18 M), 
synthesized as reported in Table 3.10, entry 6 (for entries 1-4 of Table 3.11) and 7 (for 
entry 5 of Table 3.11). The R-C path (Figure 2.27) was used to screen different 
temperatures and residence times, following the synthesis of 6 using the S-R pathway. 
The optimal conditions are given in entries 3 and 5. Conditions of entry 5 were selected 
for the final process optimization in order to avoid precipitation of intermediate 6 that occurs 
after 30 minutes when using higher concentrations. 
Table 3.11. Condition screening for step L3.a 
Entry 
 
Conc. 6 (M) T (°C) t (min) Conv. %e 
1 
 
0.25 R.T. 10 0 
2 
 
0.25 R.T. 30 b 12 
3 
 
0.25 60 20 c >95 
4 
 
0.25 60 10 d 55 
5 
 
0.18 60 20 c >95 (83%) 
a Conditions screened using the R-C path on the synthesizer; 7.5 M NH3 in H2O was used for every 
test; back pressure = 5 bar. The reaction was monitored via Flow-IR following the disappearance 
of peak at 1722 cm-1 and the formation of peaks at 1640, 1500 and 1080 cm-1. b  MFC1 = MFC2 = 
4 ml/min; effective liquid flow rate: 1.6 mL/min; stop-flow applied for 20 minutes. c MFC1 = MFC2 = 
MFC3 = 2 ml/min. d MFC1 = MFC2 = MFC 3 = 4 ml/min. e The crude mixture was dried on the 
rotavap and conversion was determined by the ratio of the integrated area of 5 to the total area for 
peaks 6 + 5 via 1H and 19F NMR in deuterated DMSO. The NMR yield was determined via 1H NMR 




3.1.2.4 Final process optimization 
Optimal conditions for the three steps were found to be: L1 (Table 3.9, entries 1, 2 
and 3), L2 (Table 3.10, entries 6 and 7), and L3 (Table 3.11, entries 3 and 5). The linear 
synthesis uses the combination of pathways R-S, S-S, S-C. As such, I identified the best 
process as: 
 
L1: (R-S), Table 3.9, entry 2 
L2: (S-S), Table 3.10, entry 6 
L3: (S-C), Table 3.11, entry 5 
 
The system was then pressurized at 5 bar and the following protocol was applied 
(Figure 3.8 and Figure 3.9- Figure 3.11). 
 
 





L1 (Figure 3.9):  
 Reagents withdrawn from vessel 2 (1) and vessel 5 (NaN3). 
 R-S pathway: product sent through port 15 of forwarding valve to the standby loop 
(intermediate 2 stored in the standby module). 
 Reactor temperature: 40 °C. 
 Back pressure: 5 bar. 
 Gas flow rate set: MFC1 = MFC2 = 9 mL/min. 
 Actual liquid flow rate: from each sample loop: 1.8 mL/min. Total liquid flow rate = 
3.6 mL/min. 
 Injection time: 0 s. 
 Cycle time: 408 s (6 min 48 s). 
 Residence time in the heated reactor: 5 min 30s. 
 
Table 3.12. Destination at all valves for step L1 
 Divergent 
Valve (E) a 
Convergent 










14 14 DRAIN LOAD 15  
Injection 
time 
14 14 2 INJECT 14 0 
Cycle time 14 14 2 LOAD 15 408 
Final 
position 





Figure 3.9. First step (L1) of the radial linear synthesis of rufinamide (R-S). Starting materials are 





L2 (Figure 3.10):  
 Reagents withdrawn from vessel 7 (3) and vessel 10 (CuI). 
 S-S pathway: reagents coming from both RDS and standby module, product sent 
through port 15 of forwarding valve towards the standby loop (intermediate 6 stored 
in the standby module). 
 Reactor temperature: 60 °C. 
 Back pressure: 5 bar. 
 Gas flow rate set: MFC1, MFC2, MFC3 = 2 mL/min. 
 Actual liquid flow rate: from each sample loop and standby loop: 0.4 mL/min. Total 
liquid flow rate = 1.2 mL/min during the injection time; 0.8 mL/min during the rest 
of the cycle. 
 Injection time: 180 s. 
 Cycle time: 1440 s (24 min). 
 Residence time in the heated reactor = 1200 s (20 min). 
 
Table 3.13. Destination at all valves for step L2 
 Divergent 
Valve (E) a 
Convergent 










14 14 DRAIN LOAD 15  
Injection 
time 
14 14 15 INJECT 14 180 
Cycle time 14 14 15 LOAD 15 1440 
Final 
position 





Figure 3.10. The second step (L2) of the radial linear synthesis of rufinamide (S-S). Starting 





L3 (Figure 3.11):  
 Reagents withdrawn from vessel 9 (NH3) and vessel 14 (H2O). 
 S-C pathway: reagents coming from both RDS and standby module, product sent 
through port 14 of forwarding valve towards a pressurized collecting vial. 
 Reactor temperature: 60°C. 
 Back pressure: 5 bar. 
 Gas flow rate set: MFC1 = MFC2m = MFC3 = 2 mL/min. 
 Actual liquid flow rate: from each sample loop and standby loop = 0.4 mL/min. Total 
liquid flow rate during injection time = 1.2 mL/min. Total liquid flow rate during rest 
of the cycle = 0.8 mL/min 
 Injection time: 180 s. 
 Cycle time: 1290 s (21 min 30 s). 
 Residence time in the heated reactor = 1200 s (20 min). 
 



















DRAIN INJECT 14 180 
Cycle time 14 14 
 










Figure 3.11. The third step (L3) of the radial linear synthesis of rufinamide (S-C). Starting materials 
are reported in blue and products in red. 
The 1H NMR yield vs 1,3,5-trimethoxybenzene was 83% over the 3 steps. 
Demineralized water (1 mL) was added to the crude solution to crystallize rufinamide, 





The different synthetic pathways to a target molecule executed on the same 
instrument allow for the direct comparison of synthetic routes. Rufinamide is achieved 
through the convergent route in a shorter time (20 minutes) compared to the linear one 
(45 minutes). Furthermore reaction conditions required in the convergent process are 
milder (the first step requires 40 °C and second and third step take place at room 
temperature). The rufinamide syntheses compared here identified the solubility of the 
heterocyclic adduct as a key challenge. Formation of this species in the final step of the 
convergent process allows for more concentrated solutions of 1 to be used (1.5 M versus 
the 1.0 M of the linear pathway) as starting materials. Rufinamide purification is simpler 
via the convergent route because the product crashes out upon exiting the instrument, 
while the linear route required the addition of water. Finally, not only is the convergent 
route higher yielding than the linear path after room temperature crystallization (70% 




3.2 Library Generation 
The ability to access multiple synthetic routes and different conditions on one 
instrument without the need of physical intervention allows for the generation of libraries 
of derivatives (Figure 3.12). This opens the door to the application of the radial synthesizer 
to fields like medicinal chemistry which are based on the systematic, synthetic alteration 
of known core structures. 
 
Figure 3.12. Library of rufinamide derivatives achievable via combination of different aryl cores and 
amine functionalities. 
Both the arene core and the amide functionality of rufinamide can be replaced by 
playing with different combinations of substrates and reagents. The synthetic pathway to 
use for the synthesis of each derivative can be chosen on the basis of the least number of 
re-optimizations required. Due to differences in reactivity between the two new sets of 
reagents, several of the steps require different reaction temperature, time, or 
concentration. By judicious choice between either the convergent or the linear route 
already optimized for rufinamide, it was possible to identify the easiest synthetic process 
for each molecule of the library saving time and efforts. For example, the arene core of 
rufinamide is introduced first in both the convergent and the linear pathways. However, for 
the convergent route, variation of this group would result in two potential re-optimizations 
(the C2 step is independent as shown in Figure 3.13 a), whereas all three steps of the 
linear path could be affected. Likewise, the amine is introduced in the last step of the linear 
pathway (only one re-optimization required), whereas two re-optimizations might be 




Figure 3.13. The synthetic route for each class of derivatives was selected based on the minimal 
number of steps potentially requiring re-optimization, which are highlighted in colored boxes. Steps 
that don´t require re-optimization are grayed.  
 Arenes scope 
The investigation started from the synthesis of derivatives 12 and 13 (Scheme 3.9) 
in which the 2,6-difluorobenzyl core of rufinamide is replaced respectively by a benzyl and 
a naphthyl core (Figure 3.12). The more straightforward way to introduce this modification 
is through the convergent synthesis because using this synthetic pathway step C2 is 
identical to step C2 of rufinamide, thus only steps C1 and C3 need to be optimized. 
 
Scheme 3.9. Synthesis of derivatives 12 and 13. The bromides scope was investigated using the 




3.2.1.1 Synthesis of benzyl azide 23 (C1/L1) 
The formation of benzyl azide 23 was first tested starting from benzyl bromide (7) 
and sodium azide, under the same conditions used to synthesize 2,6-difluorobenzylazide 
2 (Table 3.2 entry 5) using the R-C path. 
 
Scheme 3.10. Synthesis of benzyl azide 23 (C1/L1). 
The reaction did not show any phase separation and good conversion was 
achieved when the reaction was run at 40 °C for 5 minutes. The reaction was monitored 
via Flow-IR, following the formation of the peak at 2090 cm-1. In order to calculate the yield, 
one test was run in D2O, MeOD, and CH3CN. Upon collection, 0.2 mL of DMSO-d6 were 
added to the sample and the mixture was analyzed by 1H NMR spectroscopy, providing 
benzyl azide 23 in 95% conversion (the presence of non-deuterated CH3CN is the reason 
for the tall peak at 1.97 ppm in Figure 6.31 of the appendix). Note that this intermediate 
was never isolated, the spectrum in Figure 6.31 is the 1H NMR of the crude reaction.  
 
3.2.1.2 Optimization of the synthesis of 2-(azidomethyl)naphthalene 24 (C1/L1) 
Also the formation of 2-(azidomethyl)naphthalene (24) started from 2-
(bromomethyl)naphthalene (8) and sodium azide testing at first the same conditions found 
optimal for 2,6-difluorobenzylazide 2 (Table 3.2 entry 5). However, due to the poor 
solubility of bromide 8 in water, precipitation was observed as soon as the solution came 
into contact with the solution of sodium azide (which contains 35% of water).  
 
 
Scheme 3.11. Synthesis of 2-(azidomethyl)naphthalene 24 (C1/L1). 
Different concentrations and solvents ratios were screened using the R-C path on 
the synthesizer to find the best conditions. These tests are reported in Table 3. 15. The 
solution exiting the synthesizer was dried on the rotavap and analyzed via 1H NMR. 
Optimal conditions are given in entry 3. 
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Table 3. 15. Condition screening for the synthesis of 2-(azidomethyl)naphthalene 24 a 
Entry 
 
Conc. 8 (M) Conc. NaN3 (M) Solvent (NaN3) t (min) Precipitation Conv. % b 














3 0.5 0.53 
MeOH (80) 
H2O (20) 
5 none >95% 
a Conditions screened using the R-C path on the synthesizer; 8 solubilized in CH3CN:MeOH = 1:4; 
reactor temperature: 40 °C; back pressure: 5 bar; set gas flow rates: MFC1 = MFC2 = 9 mL/min. 
The reaction was monitored via Flow-IR, following the formation of the peak at 2090 cm-1. b 
Conversion determined by the ratio of the integrated area of benzylic peak of 24 to the total area 
for benzylic peaks of 8 + 24 in 1H NMR. c When precipitation was observed the reaction mixture 
was expelled as reported in the general information from the unpressurized port of the divergent 
valve E. 
 
3.2.1.3 Optimization of the synthesis of derivative 12 (C3) 
For the synthesis of 1-benzyl-1H-1,2,3-triazole-4-carboxamide (12) the same 
conditions found optimal for step C3 of the synthesis of rufinamide were initially screened.  
 
Scheme 3.12. Synthesis of derivative 12 (C3). 
Intermediate 4 (C2) was synthesized as described in Table 3.3 entry 3 using the 
R-S pathway in the synthesizer. The resulting 1 M solution of 4 was then reacted with a 
0.75 M solution of 23 and a 0.0375 M solution of CuI (Table 3.5, entry 5) using the S-C 
pathway on the synthesizer. The reaction was monitored via Flow-IR, following the 
disappearance of peak at 2090 cm-1 and the formation of peaks at 1610 and 1500 cm-1. 
Optimization of the residence time was performed by setting the flow rate of the 
three MFCs to 3 mL/min (resulting residence time in the reactor: 11 minutes). The 
residence time was adjusted progressively in order to avoid precipitation within the flow 
reactor. When precipitation was observed the mixture was expelled as reported in section 
2.2 using the unpressurized line at the forwarding valve G. Using this methodology, the 
residence time for 12 was determined to be four minutes. 
The process proceeded smoothly, with the product precipitating in the collection 
vessel 5 minutes after reagent mixing. Crystals were filtered, washed with water, and 
analyzed by 1H NMR spectroscopy. The 1H NMR NMR yield of the crude material vs 1,3,5-




3.2.1.4 Optimization of the synthesis of derivative 13 (C3) 
 
Scheme 3.13. Synthesis of derivative 13 (C3). 
Compound 24 was synthesized as reported in Table 3. 15, entry 3 (final 
concentration of 24 was 0.25 M) and stored in the RDS (R-R path on the synthesizer). 
Propiolamide 4 was prepared as reported in Table 3.3, entry 4 (final concentration of 4 
was 0.5 M) and stored in the SM using the R-S path on the synthesizer. A solution of CuI 
(0.0125 M in CH3CN) is accessed from the RDS and C3 is performed using the S-C path. 
The reaction was monitored via Flow-IR, following the disappearance of peak at 2090 cm-
1 and the formation of peaks at 1651, 1640, and 1029 cm-1. 
After a residence time of 8 minutes, precipitation was observed. The reaction 
mixture was then expelled from the synthesizer as reported in section 2.2 using the 
unpressurized line at the forwarding valve G. After stirring for 15 minutes the crystals of 
derivative 13 are filtered, washed with demineralized water, and analyzed via 1H NMR. 
NMR yield (77%) was calculated via 1H NMR vs 1,3,5-trimethoxybenzene as standard. 
The yield of the crystallized material (13) was 52%.  
 Amines scope 
In order to vary the amide group of rufinamide, the more straightforward way is 
through the linear synthesis. The syntheses of rufinamide derivatives which share the 2,6-
difluorobenzyl core indeed, do not need any optimization until the very last step (L3) when 
following the linear route (Scheme 3.14). 
 
Scheme 3.14. Synthesis of derivatives 14, 17 and 20. The amines scope was investigated using 




3.2.2.1 Optimization of the synthesis of derivative 17 (L3) 
 
Scheme 3.15. Synthesis of derivative 17 (L3). 
Intermediate 6 was synthesized following the same protocol already developed for 
the linear synthesis of rufinamide: L1 (R-S, Table 3.9, entry 2), L2 (S-S, Table 3.10, entry 
6). A series of tests varying concentration, temperature, and residence time were 
performed in order to optimize L3 for alkyl amines. 
Neat propylamine was loaded in one of the vessels of the reagent selector A and 
diluted with acetonitrile coming from the solvent selector S to screen different 
concentrations. Stoichiometry, temperature, and residence time were screened using the 
S-C pathway and results are given in Table 3.16. 
Table 3.16. Condition scouting synthesis of derivative 17.a 
Entry 
 
Conc. 10 T (°C) t (min) Conv. %b 
1 
 
6 M 60 10c 50 
2 
 
6 M 100 10c 50 
3 
 
Neat (12 M) 100 10c 87 
4 
 
Neat (12 M) 100 20d >95% 
a Conditions screened using the S-C pathway on the synthesizer; conc. of 6 0.5 M; back pressure 
5 bar. The reaction was monitored via Flow-IR following the disappearance of peak at 1722 cm-1 
and the formation of peaks at 2880, 1615, 1605 and 1315 cm-1. b Conversion determined by the 
ratio of the integrated area of the triazole peak of 17 to the total area for the triazole peaks of 6 + 
17 in 1H NMR. c Set gas flow rates: MFC1 = MFC2 = MFC3 = 3.5 mL/min. d Set gas flow rates: 
MFC1 = MFC2 = MFC3 = 2 mL/min. No precipitation was observed. 
 
Water (1 mL) was added to the collected crude mixture to crystallize derivative 17. 
The NMR yield (86%) was determined for this derivative via 1H NMR vs 1,3,5-
trimethoxybenzene. After stirring for 4 hours at room temperature, 9.4 mg of compound 17 
was obtained (40% yield).  
3.2.2.2 Optimization of the synthesis of derivative 14 (L3) 
 
Scheme 3.16. Synthesis of derivative 14 (L3). 
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Intermediate 6 was synthesized following the same protocol developed for the 
linear synthesis of rufinamide: L1 (R-S, Table 3.9, entry 2), L2 (S-S, Table 3.10, entry 6). 
The same conditions of Table 3.16, entry 4 were tested using ethylamine (70% solution in 
water) for L3 using the S-C pathway. The reaction was monitored via Flow-IR, following 
the disappearance of peak at 1722 cm-1 and the formation of peaks at 2880, 1605, 1500, 
and 1316 cm-1. No precipitation was observed. 
Upon collection, the solvent was evaporated, and the residue was analyzed by 1H 
NMR (74% vs 1,3,5-trimethoxybenzene. Water (1 mL) was added to the collected crude 
mixture to crystallize derivative 14. After stirring for 4 hours at room temperature, 10.2 mg 
of pure compound was obtained (46% yield). 
3.2.2.3 Optimization of the synthesis of derivative 20 (L3) 
 
Scheme 3.17. Synthesis of derivative 16 (L3). 
Intermediate 6 was synthesized following the same protocol developed for the 
linear synthesis of rufinamide: L1 (R-S, Table 3.9, entry 2), L2 (S-S, Table 3.10, entry 6). 
Based on the assumption that allylamine is a worse nucleophile than propylamine, I 
excluded the possibility that a dilute solution or temperature lower than 100 °C could result 
in a good yield. As such, a series of tests were chosen for step L3 starting with neat 
allylamine and screening different residence times using the S-C pathway on the 
synthesizer. The results are shown in Table 3.17. Stop-flow conditions were utilized to 
achieve residence times longer than 20 minutes. 
Table 3.17. Condition scouting synthesis of derivative 20.a 
Entry 
 
Conc. 11 T (°C) t (min) Conv. %b 
1 
 
Neat 100 20c 50% 
2 
 
Neat 100 40d 72% 
3 
 
Neat 100 60d 86% 
a Conditions screened using the S-C path on the synthesizer; conc. of 6 0.5 M; pressure = 5 bar. 
The reaction was monitored via Flow-IR following the disappearance of peak at 1722 cm-1 and the 
formation of peaks at 1670, 1596, 1315 and 1202 cm-1. b Conversion determined by the ratio of the 
integrated area of the triazole peak of 20 to the total area for the triazole peaks of 6 + 20 in 1H NMR. 
No precipitation was observed. c Set gas flow rates: MFC1 = MFC2 = 2 mL/min. d Set gas flow 
rates: MFC1 = MFC2 = 4.5 mL/min, stop-flow for the time necessary to achieve the specified 




NMR yield (58%) was determined for this derivative via 1H NMR vs 1,3,5-
trimethoxybenzene. Water (1 mL) was added to the collected crude mixture to crystallize 
derivative 20. After stirring for 4 hours at room temperature, 4.5 mg of pure compound was 
obtained (29% yield).  
 Mixed derivatives 
Finally, a series of derivatives were prepared by combining two arene cores (benzyl 
bromide 7 and 2-(bromomethyl)Naphthalene 8) with three alkyl amines 9, 10 and 11. 
These mixed derivatives can be grouped in two sets: derivatives sharing the benzyl core 
(15,18 and 21 in Figure 3.12) and derivatives sharing the naphthyl core (16, 19 and 22 in 
Figure 3.12). Once the two sets were identified the potential optimizations required by both 
the linear and the convergent route were investigated.  
I envisioned that the linear route would give the fastest access to the mixed 
derivatives as it requires two individual optimizations for step L2, leading to intermediates 
25 and 26 and three optimizations of step L3 for each intermediate (2 + 6 = 8 step 
optimizations), while the convergent process would require new conditions for each amide 
formation (intermediates 27, 28 and 29) resulting in three re-optimizations for step C2 and 
following combination of each of them with the two azides (intermediates 23 and 24) 





Figure 3.14. Convergent vs linear route for the syntheses of mixed derivatives (15, 16, 18, 19, 21 
and 22). The linear route resulted being the most convenient pathway as it requires 8 vs 9 potential 
step re-optimizations. 
3.2.3.1 Optimization of the synthesis of intermediate 25 
 
Scheme 3.18. Synthesis of intermediate 25 (L2). 
Intermediate 23 was synthesized following the optimal protocol found for 2,6-
difluorobenzylazide 2 (Table 3.9, entry 5) using the R-S pathway on the synthesizer. The 
resulting 0.375 M solution of 23 was then combined with methyl propiolate 3 and CuI 
applying the same optimal conditions found for the synthesis of intermediate 6 (Table 3.10, 
entry 7) using the S-C pathway. The reaction was monitored via Flow-IR, following the 
disappearance of peak at 2090 cm-1 and the formation of peak at 1722 cm-1. No 
precipitation was observed. 
Upon collection, the solvent was evaporated and the residue was analyzed by 1H 
NMR, showing conversion >95% (conversion determined by the ratio of the integrated 
area of benzylic peaks of 25 to the total area for benzylic peaks of 23 + 25 in 1H NMR).  
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3.2.3.2 Optimization of the synthesis of intermediate 26 
 
Scheme 3.19. Synthesis of intermediate 26 (L2). 
Intermediate 24 was synthesized as described in Table 3. 15, entry 3 using the R-
S pathway on the synthesizer. The resulting 0.25 M solution of 24 was then combined with 
methyl propiolate 3 and CuI, applying conditions similar to those reported in Table 3.11, 
entry 7, with some adjustments due to the lower initial concentrations of starting material: 
24 (0.25 M), CuI (0.0125M), 3 (1 M). The reaction was performed using the S-C path and 
monitored via Flow-IR, following the disappearance of peak at 2090 cm-1 and the formation 
of peak at 1722 cm-1. No precipitation was observed. 
Upon collection, the solvent was evaporated and the residue was analyzed by 
1HNMR, showing conversion >95% (conversion determined by the ratio of the integrated 
area of benzylic peak of 26 to the total area for benzylic peaks of 24 + 26 in 1H NMR).  
3.2.3.3 Synthesis of derivative 18 (L3) 
 
Scheme 3.20. Synthesis of derivative 18 (L3). 
Intermediate 25 was synthesized as reported in section 3.2.3.1, using the S-S 
pathway on the synthesizer. The same optimal conditions found for the synthesis of 
derivative 17 were applied (Table 3.16, entry 4) to run the reaction between intermediate 
25 and propylamine 10 using the S-C pathway. The reaction was monitored via Flow-IR, 
following the disappearance of peak at 1722 cm-1 and the formation of peaks at 2880, 
1605, and 1150 cm-1. No precipitation was observed. 
Upon collection, the solvent was evaporated, and the residue was analyzed by 1H 
NMR. NMR yield (83%) was determined for this derivative via 1H NMR vs 1,3,5-
trimethoxybenzene. Water (1 mL) was added to the collected crude mixture to crystallize 
derivative 18. After stirring for 4 hours at room temperature, 7.7 mg of pure compound was 
obtained (38% yield). 
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3.2.3.4 Synthesis of derivative 19 (L3). 
 
Scheme 3.21. Synthesis of derivative 19 (optimization of L3). 
Intermediate 26 was synthesized as reported in section 3.2.3.2, using the S-S 
pathway on the synthesizer. The same optimal conditions found for the synthesis of 
derivative 17 were applied (Table 3.16, entry 4) to run the reaction between intermediate 
26 and propylamine 10 using the S-C pathway. The reaction was monitored via Flow-IR, 
following the disappearance of peak at 1722 cm-1 and the formation of peaks at 2880, 
1615, 1315, and 1150 cm-1. No precipitation was observed. 
Upon collection, the solvent was evaporated, and the residue was analyzed by 1H 
NMR. NMR yield (79%) was determined for this derivative via 1H NMR vs 1,3,5-
trimethoxybenzene. Water (1 mL) was added to the collected crude mixture to crystallize 
derivative 19. After stirring for 4 hours at room temperature, 2.4 mg of pure compound was 
obtained (20% yield). 
3.2.3.5 Synthesis of derivative 21 (L3). 
 
Scheme 3.22. Synthesis of derivative 21 (optimization of L3). 
Intermediate 25 was synthesized as reported above in the related paragraph 
3.2.3.1 using the S-S pathway on the synthesizer. The same optimal conditions found for 
the synthesis of derivative 20 were applied (Table 3.17, entry 3) to run the reaction 
between intermediate 25 and allylamine 11 using the S-C pathway. The reaction was 
monitored via Flow-IR, following the disappearance of peak at 1722 cm-1 and the formation 
of peaks at 2880, 1645, 1605, and 1150 cm-1. No precipitation was observed. 
Upon collection, the solvent was evaporated, and the residue was analyzed by 1H 
NMR. NMR yield (75%) was determined for this derivative via 1H NMR vs 1,3,5-
trimethoxybenzene. Water (1 mL) was added to the collected crude mixture to crystallize 
derivative 21. After stirring for 4 hours at room temperature, 4.4 mg of pure compound was 
obtained (22% yield). 
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3.2.3.6 Synthesis of derivative 22 (L3) 
 
Scheme 3.23. Synthesis of derivative 22 (optimization of L3). 
Intermediate 26 was synthesized as reported in section 3.2.3.2, using the S-S 
pathway on the synthesizer. The same optimal conditions found for the synthesis of 
derivative 20 were applied (Table 3.17, entry 4) to run the reaction between intermediate 
26 and allylamine using the S-C path. The reaction was monitored via Flow-IR, following 
the disappearance of peak at 1722 cm-1 and the formation of peaks at 2880, 1675, 1615, 
1500, 1312, and 1205 cm-1. No precipitation was observed. 
Upon collection, the solvent was evaporated, and the residue was analyzed by 1H 
NMR. NMR yield (76%) was determined for this derivative via 1H NMR vs 1,3,5-
trimethoxybenzene. In order to crystallize derivative 22, the volume of the solution exiting 
the synthesizer was reduced for 20 minutes on the rotavap with the bath set at room 
temperature. Water (1 mL) was then added. After stirring for 4 hours at 0 °C, 2.1 mg of 
pure compound was obtained (17% yield). 
3.2.3.7 Synthesis of derivative 15 (L3). 
 
Scheme 3.24. Synthesis of derivative 15 (optimization of L3). 
Intermediate 25 was synthesized as reported in the related paragraph 3.2.3.1, 
using the S-S pathway. The same conditions of Table 3.16, entry 4 were tested using 
ethylamine (70% solution in water) for L3 using the S-C pathway. The reaction was 
monitored via Flow-IR, following the disappearance of peak at 1722 cm-1 and the formation 
of peaks at 2880, 1605, 1500, and 1150 cm-1. No precipitation was observed. 
Upon collection, the solvent was evaporated, and the residue was analyzed as it 
was by 1H NMR. NMR yield (80%) was determined for this derivative via 1H NMR vs 1,3,5-
trimethoxy benzene. Water (1 mL) was added to the collected crude mixture to crystallize 
derivative 15. After stirring for 4 hours at room temperature, 6.7 mg of pure compound was 
obtained (35% yield). 
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3.2.3.8 Synthesis of derivative 16 (L3). 
 
Scheme 3.25. Synthesis of derivative 16 (optimization of L3). 
Intermediate 26 was synthesized as reported in section 3.2.3.2 using the S-S 
pathway. The same conditions of Table 3.16 entry 4 were tested using ethylamine (70% 
solution in water) for L3 using the S-C pathway. The reaction was monitored via Flow-IR 
following the disappearance of peak at 1722 cm-1 and the formation of peaks at 2880, 
1615, 1395, and 1150 cm-1. No precipitation was observed. 
Upon collection, the solvent was evaporated, and the residue was analyzed without 
any further purification by 1H NMR. NMR yield (75%) was determined for this derivative 
via 1H NMR vs 1,3,5-trimethoxybenzene. In order to crystallize derivative 16, the volume 
of the solution exiting the synthesizer was reduced for 20 minutes at the rotavap with the 
bath set at room temperature. Water (1 mL) was then added. After stirring for 4 hours at 0 




3.3 Modular expansion 
The next feature of the radial synthesizer that we wanted to validate was the ability 
to easily connect new modules to the central station. With this goal in mind, we integrated 
a simple setup for flow-photoreactions composed of a 10 mL FEP tube (internal diameter 
0.8 mm) and a LED lamp 420 nm, 72 W (Figure 3.15).  
 
Figure 3.15. Flow-photoreactor 
The integration of this new module was achieved by connecting the inlet and outlet 
of the coil reactor to port number 12 of both the divergent and convergent valves (E and 
F) of the CSS (using standard flow connectors) and introducing an on/off switch for the 
light source in the software interface. 
Through the addition of this photochemical module, a wider and more diverse 
range of chemical processes could be performed on the same system. Dual 
nickel/photoredox-catalyzed cross-couplings were chosen to showcase the new 
capabilities of the radial synthesizer because they constitute a powerful synthetic 
methodology33 for the formation of carbon-carbon34 and carbon-heteroatom bonds, e.g. 
the C-N bonds of aniline derivatives35.  
Building on previous studies35, the optimization of the coupling of pyrrolidine and 
1-bromo-4-(trifluoromethyl)benzene (30) was performed as a two-step process (R-R, R-C) 
using the 420 nm LED photoreactor and flow-NMR modules. With conditions in hand, a 
series of couplings were sequentially performed using solutions of 
Ir(dF(CF3)ppy]2(dtbpy))PF6), NiBr2 and DABCO (1,4-diazabicyclo[2.2.2]octane) with either 
30 or 1,4-dibromobenzene (31) and a series of secondary amines (pyrrolidine 32, 
pyrrolidin-3-ol 33, and piperidin-4-ol 34) to provide aniline derivatives (35, 36, 37 and 38) 




Figure 3.16. Library of new compounds achievable through photochemical processes  
 
 General procedure for flow metallophotoredox process 
 
Scheme 3.26. Synthesis of aryl amines via dual nickel-photoredox catalysis processes 
Following a flow protocol already established by MacMillan et al.35, solutions of 
different aryl bromides (30, 31), cyclic amines (32, 33 and 34), NiBr2 ● 3H2O, 
(Ir[dF(CF3)ppy]2(dtbpy))PF6 (Ir cat) and 1,4-diazabicyclo[2.2.2]octane (DABCO) in 
dimethyl acetamide (DMA) were loaded in the reagents pool of the radial synthesizer.  
The order of mixing of the reactants turned out to be irrelevant. All the reaction 
mixture components can be mixed together with nothing happening until they are exposed 
to the blue light ((control experiments performed without irradiation for every reaction 
showed no conversion after 16 hours). To avoid the quenching of the Iridium photocatalyst 
excited state by dissolved oxygen, all solutions were degassed by bubbling Argon through 
them for 10 minutes before loading them in the reagent delivery system. 
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Vessel 1: empty (used for storage of products 35, 36 and 37 to 
allow a second cycle through flow-NMR for in-line analysis) 
Vessel 2: 1-bromo-4-(trifluoromethyl)benzene (30) + NiBr2 ● 
3H2O, Ir cat + DABCO 
Vessel 3: empty 
Vessel 5: 1,4-dibromobenzene (31) + NiBr2 ● 3H2O, Ir cat + 
DABCO 
Vessel 6: empty 
Vessel 7: pyrrolidine (32) 
Vessel 8: empty 
Vessel 9: pyrrolidin-3-ol (33) 
Vessel 10: piperidin-4-ol (34) 
Vessel 11: empty 
Vessel 13: DMA 
Vessel 14: DMA 
 
Different combinations of reactants, as well as different ratios of NiBr2, Ir catalyst 
and DABCO, were screened under different residence time and light voltage.  
A first cycle (P1) was programmed to send the reaction mixture to port 12, 
connected to the 10 mL photoreactor and then store the product in the reagent delivery 
system using the R-R pathway. A second cycle (P2) then mixed the product with 
deuterated DMSO and sent the mixture towards port 15 connected to the flow-NMR. The 
19F NMR of the sample was measured while the stop-flow mode was selected for 10 
minutes. Using the R-C pathway, the final mixture was collected in the collection vessel. 
 
 
Figure 3.17. Five reagents were loaded in the RDS and combined to generate the library of Figure 3.16. 
White vessels were left empty and grey dots represent ports that are dedicated to other purposes than 





Figure 3.18. Step P1 for the synthesis of aryl amines (R-R pathway). Starting materials are reported 











3.3.1.1 Synthesis of 1-(4-(trifluoromethyl)phenyl)pyrrolidine (35) (P1, P2). 
 
Scheme 3.27: Synthesis 1-(4-(trifluoromethyl)phenyl)pyrrolidine (35). 
A solution of 4-bromobenzotrifluoride (30) 0.27 M, NiBr2 ● 3H2O 5%, Ir cat. 0.2% 
and DABCO 1.8 equiv. in DMA and a solution of pyrrolidine 32 1.5 equiv. in DMA were 
mixed and sent through the photoreactor using the R-R pathway (sending the outcoming 
solution back to the RDS). The system was pressurized at 5 bar and 0.5 mL/min flow rate 
for the three MFCs was set resulting in a 1-hour residence time (P1). A second cycle (P2) 
was performed mixing the solution coming from step P1 with deuterated DMSO and 
opening port 15 (connected to the flow-NMR in the CSS) using the R-C pathway. A 5-bar 
pressure was applied also for this step and flow rate was set at 2.5 mL/min for the three 
MFC. The time necessary for injection was 99 seconds and after that a 10 minutes stop-
flow mode was applied, switching to port 2 for 10 minutes and finally reopening port 12 
once the NMR experiment was over, (see section 2.1.3.2). 
The inline 19F NMR analysis showed a conversion >95%.  
 




In order to corroborate the results of the flow-NMR the same solution was 
transferred in an NMR tube and analyzed on a Varian 400 MHz Varian adding 1 equiv. of 
4-fluorotoluene as internal standard to measure the NMR yield. The conversion was found 
to be 87%. 
 
Figure 3.21. 19F NMR spectrum collected through Varian 376 MHz NMR. 
The remaining solution (≈ 0.5 mL left in the RDS) was concentrated and the residue 
purified by column chromatography (eluent Hexane:Et2O 8:2) giving 61% isolated yield. 
3.3.1.2 Synthesis of 1-(4-bromophenyl)pyrrolidine (38) (P1). 
 
Scheme 3.28. Synthesis 1-(4-bromophenyl)pyrrolidine (38). 
Due to the absence of a fluorinated moiety in the molecule was not possible to 
exploit the flow-NMR spectrometer and measure the conversion of this reaction on-line, 
therefore this process was composed of only step P1 and yield was measured offline. 
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A solution of 1,4-dibromobenzene (31) 0.27 M, NiBr2 ● 3H2O 5%, Ir cat 0.2% and 
DABCO 1.8 equiv. in DMA and a solution of pyrrolidine 32 1.5 equiv. in DMA were mixed 
and sent through the photoreactor using the R-R pathway (sending the outcoming solution 
back to the RDS). A pressure of 5 bar was applied and 0.5 mL/min flow rate for the 3 MFCs 
was set resulting in a 1-hour residence time. The resulting solution was concentrated and 
the residue purified by column chromatography (eluent Hexane:Et2O 8:2) giving 35% 
isolated yield. 
3.3.1.3 Synthesis of 1-(4-(trifluoromethyl)phenyl)pyrrolidin-3-ol (36) (P1 + P2). 
 
Scheme 3.29. Synthesis 1-(4-(trifluoromethyl)phenyl)pyrrolidin-3-ol (36). 
A solution of 4-bromobenzotrifluoride (30) 0.27 M, NiBr2 ● 3H2O 5%, Ir cat. 0.2% 
and DABCO 1.8 equiv. in DMA and a solution of pyrrolidin-3-ol (33) 1.5 equiv. in DMA 
were mixed and sent through the photoreactor using the R-R pathway (sending the 
outcoming solution back to the RDS). A pressure of 5 bar was applied and 0.5 mL/min flow 
rate for the 3 MFCs was set resulting in a 1-hour residence time (P1).  
A second cycle (P2) was performed mixing the solution coming from step P1 with 
deuterated DMSO and opening port 15 (connected to the flow-NMR in the CSS) using the 
R-C pathway. A 5-bar pressure was applied also for this step and flow rate was set at 2.5 
mL/min for the 3 MFC. 99 seconds were necessary for injection time and after that a 10 
minutes stop-flow mode (see section 2.1.3.2). The inline 19F NMR analysis showed a 
conversion of 52%.  
Different ratios of pyrrolidin-3-ol 33, NiBr2 ● 3H2O, Ir cat and DABCO as well as 
different light voltage and residence time were then screened to improve the conversion 
of this reaction. The results for these tests are reported in Table 3.18. 
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Table 3.18. Condition scouting synthesis of derivative 36.a 
Entry 
 
NiBr2 (%) Ir cat (%) 33 (equiv.) DABCO (equiv.) t (h) light (V) Conv.%d 
1 
 
5 0.2 1.5 1.8 1 h 36 52 
2 
 
5 0.4 1.5 1.8 1 h 36 58 
3 
 
5 0.02 1.5 1.8 1 h 36 24 
4 
 
5 0.2 5 1.8 1 h 36 17 
5 
 
5 0.2 1.5 1.8 1 h 30 51 
6 
 
5 0.2 1.5 1.8 2 hb 30 76 
7 
 
5 0.2 1.5 3.6c 1 h 36 95 
8 
 
10 0.2 1.5 1.8 1 h 36 >95 
a 24 0.27 M; back pressure: 5 bar; set gas flow rates: MFC1 = MFC2 = 0.5 mL/min. b to achieve the 
longer residence time stop-flow mode was used: gas stream diverted to port 2 for 1 h. c using double 
the amount of DABCO caused the formation of a sticky solid which was a risk for clogging the 
system. When this was observed the reaction mixture was expelled as reported in the general 
information from the unpressurized port of the divergent valve E. d conversion measured by 
determining the ratio of the integrated areas of the peak at −61.6 ppm belonging to 30 and the area 
of the new peak at −59.1 ppm in the 19F NMR spectrum. 
 
The resulting solution was concentrated, and the residue was solubilized in Et2O 
and washed with brine. Organic layers were concentrated giving 58% isolated yield. 
3.3.1.4 Synthesis of 1-(4-(trifluoromethyl)phenyl)piperidin-4-ol (37) (P1 + P2). 
 
Scheme 3.30. Synthesis 1-(4-(trifluoromethyl)phenyl)piperidin-4-ol (37). 
 
Considering the presence of the hydroxyl group I decided to start from the optimal 
conditions found for compound 36 (Table 3.18, entry 8). A solution of 4-
bromobenzotrifluoride (30) 0.27 M, NiBr2 ● 3H2O 10%, Ir cat. 0.2% and DABCO 1.8 equiv. 
in DMA and a solution of piperidin-4-ol 34 1.5 equiv. in DMA were mixed and sent through 
the photoreactor using the R-R pathway (sending the outcoming solution back to the RDS). 
A pressure of 5 bar was applied and 0.5 mL/min flow rate for the 3 MFCs was set, resulting 
in a 1-hour residence time (P1). A second cycle (P2) was performed mixing the solution 
coming from step P1 with deuterated DMSO and opening port 15 (connected to the flow-
NMR in the CSS) using the R-C pathway. A 5-bar pressure was applied also for this step 
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and flow rate was set at 2.5 mL/min for the 3 MFC. 99 seconds were necessary for injection 
time and after that a 10 minutes stop-flow mode (see section 2.1.3.2). 
Inline 19F NMR analysis was not possible due to overlap with the debrominated 
side product. Offline 19F NMR analysis showed a conversion of 76%. 
 
The resulting solution was concentrated and the residue solubilized in Et2O and 




3.4 Comparison of radial and continuous flow 
The validations reported in the previous sections show that the radial synthesizer 
is optimal for the discovery stage of a synthetic process. It uses only a few milliliters of 
reagent solutions and it is capable of adjusting reaction conditions and reaction stream 
pathways in an automated manner, thus allowing for the rapid screening of multiple 
synthetic options while wasting a minimum amount of material.  
Reproducibility is another important advantage of automated systems and so far, 
we observed high reproducibility when transferring a synthesis from the published 
continuous flow conditions to radial flow. Next, we wanted to showcase that reactions 
optimized using our radial synthesizer can be translated (in terms of temperature, 
pressure, concentration and residence time) in a continuous flow system such as a 
commercially available Vapourtec R4, for scale-up.  
The only difference between the two approaches is the way reagents are delivered 
and passed through the system because the actual modules where reactions take place 
are the same. Therefore, we expected to see similar, if not the same, results when applying 
the same conditions. With this last demonstration of the capabilities of our instrument, we 
wanted to demonstrate that the step from the discovery stage using the radial paradigm to 
the scale-up in a continuous flow system is as easy and straightforward as for synthetic 
processes fully developed in continuous flow. In this way, identification of the optimal 
synthetic process could be achieved with the automated radial synthesizer, wasting a 
minimum amount of materials, and then repeated on a larger scale using a commercial 
continuous flow system.  
To showcase the importance of rapid access to new convenient routes to 
pharmaceuticals combined with an effortless scale-up we chose to carry out a study on 
the synthesis of two drugs which were listed among medications in short supply in 
Germany during the COVID-19 pandemic36: paracetamol37 and nifedipine38,39. Additionally, 
we investigated also the synthesis of lidocaine25 (Figure 3.22).  
 
Figure 3.22. Three examples from the WHO list of essential APIs that served as examples for 
comparing radial and continuous flow synthesis. A painkiller 1, a local anesthetic 2 and a 
hypertension drug 340. 
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 Synthesis of paracetamol (39) 
Paracetamol is one of the most commonly used and inexpensive painkillers, yet it 
was in short supply in Germany during the COVID-19 pandemic in early 2020. Aiming at 
developing a scalable process to produce paracetamol from starting materials available in 
Europe, I evaluated the possible starting points for the synthesis. Phenol41, 4-nitrophenol42 
and 4-aminophenol37 can serve as starting materials and I identified 4-aminophenol as the 
most cost-efficient starting material (Figure 3.23 a). An alternative route starts from 
hydroquinone and uses ammonium acetate for both formation of para-aminophenol and 
its acetylation43 (Figure 3.23 b), but it is again more expensive than the simple acetylation 
of para-aminophenol. 
 
Figure 3.23. Starting materials candidates for the synthesis of paracetamol. Prices on Merck´s web 
catalog up to date 08/07/2020. 
The greenest process for the acetylation of para-aminophenol uses water as a 
solvent41. However, 4-Aminophenol (42) has poor solubility in water, making it difficult to 
obtain a homogeneous solution that is required for the flow process. On the contrary, 42 
is readily soluble when acetic anhydride (43) is added to the mixture. After screening 
different solvents, I found that acetic acid is also a good solvent for 42. Attempting to keep 
water as the main solvent, I investigated the solubility of 42 in a mixture of water/acetic 
acid and I found that one millimole of 42 is soluble in 0.5 mL of a 4:1 mixture of water and 
acetic acid. Acetic anhydride (43), on the other hand, is not miscible with water, therefore 
I decided to use it as a neat reagent. 
3.4.1.1 Optimization of the synthesis of paracetamol (39) in the radial synthesizer 
A 2 M solution of 4-aminophenol (42) in a mixture of water/acetic acid (4:1) and 
neat acetic anhydride (43) were loaded in the reagent delivery system of the radial 
synthesizer. Screening of solvents, temperature, stoichiometries and residence times for 
the acetylation of 4-aminophenol (42) was performed selecting the R-C pathway, using 0.5 




Figure 3.24. Process optimization for the synthesis of paracetamol carried out in the radial 
synthesizer using the R-C pathway 
The results, summarized in Table 3.19 revealed that full conversion of 42 to 39 is 
achieved after only five minutes at room temperature with no precipitation observed when 
using neat acetic anhydride (43) (Table 3.19, entry 9). Reducing the amount of 43, which 
is a good solvent for paracetamol (39), resulted in direct crystallization of the product. 
Crystallization started after ten minutes from addition when working with three equivalents 




Table 3.19. Conditions screening for acetylation of 4-aminophenol (42) 
Entry 
 
Conc. 42 (M) Solvent of 42 Equiv. 43 Solvent of 43 T (° C) t (min) Yield % 
1 
 
2 H2O 3 - 60 5 93a 
2 
 
2 H2O 3 - R.T. 5 94a 
3 
 






























5 (neat) - R.T. 5 (>99)c 
a Results for batch test, due to poor solubility of 42 in H2O and/or lack of miscibility of 43 with H2O, 
this test could not be carried out in the radial synthesizer. Product 39 precipitates after less than 10 
minutes after reaction completion. The reported yield is the crystallized yield after 1 h stirring at 
room temperature. b Test in radial synthesizer. The product 39 precipitates after less than 10 
minutes from collection. The reported yield is the crystallized yield after 1 h stirring at room 
temperature upon collection in an unpressurized vessel. c Test in radial synthesizer. Product 39 
does not precipitate. The result reported in parenthesis is the conversion of the starting material 
calculated from the 1H NMR of the crude, by the ratio of the integrated area of the aromatic peaks 






Figure 3.25. The synthesis of paracetamol was optimized using the R-C pathway in the radial 
synthesizer. Reagents are delivered by the RDS, pass through a heated or room temperature coil 
and the product is collected in a non-pressurized collection vessel (C). Starting materials are 
reported in blue and products in red. 
3.4.1.2 Scale-up of the synthesis of paracetamol (39) in continuous flow 
This process was scaled up using a Vapourtec R2 pump module, feeding a 2 M 
solution of 42 in water/acetic acid 4:1 from pump A and neat acetic anhydride (43) from 
pump B. When a 10 mL coil reactor was used, the two feeds were set respectively at 1.5 
and 0.45 mL/min and the resulting solution was collected upon reaction in a flask and 
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stirred at room temperature for 1 h. After running the system for 15 minutes I achieved 
6.36 g of crystallized 39 (94% crystallization yield) (Figure 3.26).  
 
Figure 3.26. Continuous flow synthesis of paracetamol carried out using a Vapourtec R2 pump 
module and a room temperature reactor coil (10 mL) in PFA (i.d. 0.8 mm). Direct crystallization of 
the product was achieved by stirring the solution exiting the flow setup for 1 h. 
Since crystallization happens spontaneously after reaction completion, without the 
need for any antisolvent addition and/or heating/cooling operations, I envisioned the 
possibility of telescoping an in-line flow-crystallization module. This module was based on 
the SMBR (serial micro-batch reactors) technique44 that generates a segmented flow, 
spaced by nitrogen, which can carry slurries minimizing clogging phenomena that 
generally affect solid-liquid systems in flow.  
The flow crystallization module was built by wrapping a 20 mL PFA coil (i.d. 1.6 
mm) around a 1 L glass bottle which can be used to control the temperature by filling it 
with an appropriate liquid/mixture and heating it up or cooling it down. Connecting one end 
of the crystallization coil with the outlet of the reactor and a nitrogen gas feed through a 
Tee junction generated the segmented flow (Figure 3.27).  
In order to allow longer residence times in the crystallization module the 10 mL coil 
reactor originally used for the continuous flow scale-up of the synthesis of 39 was replaced 
with a 1.5 mL one and flow rates were dropped at 0.25 mL/min and 0.075 mL/min 
respectively for pump A and pump B. N2 flow rate was set at 0.5 mL/min. Crystallization 
occurs in droplets and the slurry exiting the telescoped process is directly filtered to give 
pure crystals of paracetamol. Collecting for 15 minutes on the filter I achieved 634.7 mg of 
paracetamol (56%) after a 30 minutes residence time in the crystallization module at 25 
°C. This value, to some extent, reflected the results achieved with the batch crystallization. 
Stirring for one hour at room temperature in batch gave a 95% yield (Table 3.19, entry 4), 
while 30 minutes of flow crystallization gave 56%.  
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Attempts to increase the residence time in the flow-crystallization module to 1 hour 
(comparable to batch crystallization process) were made, however, using a lower flow rate 
was not possible due to the limits of the Vapourtec pumps (minimum flow rate achievable 
is 0.05 mL/min). Resizing the crystallization module from 20 to 40 mL raised the 
crystallization yield to 93%, although after 3 minutes of collection a destabilization of the 
segmented flow, due to clogging phenomena, was observed. Lowering the temperature 
from 25 to 5 °C by filling the glass bottle with water and ice did not lead to a significant 
increase in the yield. 
 
Figure 3.27. Continuous flow synthesis of paracetamol followed by flow crystallization and filtration. 
Considering that the productivity of a process is dependent on the flow rate applied, 
the flow synthesis followed by batch crystallization (Figure 3.26) was more efficient, as it 
allows for the preparation of 25.6 g/h of paracetamol. This translates to about 1229 
doses/day if we consider that one dose is one tablet (500 mg of active ingredient). At its 
best (not considering clogging issues), the flow crystallization could yield 4 g/h of 
paracetamol, due to the lower flow rate necessary to reach the 1 hour residence time in 
the crystallization module. For the scale-up of the synthesis of paracetamol, I therefore 
opted for the setup described in Figure 3.26.  
 Synthesis of lidocaine (40) 
Lidocaine is a widely employed local anesthetic45 produced via a two-step process. 
In the first step 2,6-dimethyl aniline (44) reacts with chloroacetyl chloride (45) to give the 
corresponding 2-chloro-N-(2,6-dimethylphenyl)acetamide (46), and in the second step, 
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diethylamine (47) substitutes the other chlorine atom giving the final product (Scheme 
3.31). 
 
Scheme 3.31. Two-step synthesis of lidocaine 40 
Flow syntheses of lidocaine were already reported in several works24,25,46, some 
involving automated synthesizers24,25 therefore we started developing the process testing 
the published conditions. 
3.4.2.1 Optimization of the synthesis of 40 in the radial synthesizer 
The reagent delivery system was loaded with a solution of 2,6-dimethyl aniline (44) 
in N-methyl-2-pyrrolidone (NMP) and a solution of chloroacetyl chloride (45) in NMP to 
screen the conditions for the first step using the R-C path.  
 
Figure 3.28. Process optimization for the synthesis of lidocaine carried out in the radial synthesizer 
using the R-S path for the first step and the S-C path for the second step 
The reaction is completed in ten minutes at room temperature (Table 3.20, entry 
3) compared to the 120 °C reported in literature24,25. 
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Table 3.20. Screening of conditions for the synthesis of intermediate 46 (Li-1). 
Entry Conc. 44 (M) Solvent of 
44 
Equiv. 45 Solvent of 
45 




1 NMP 1.15 NMP 120 20 -c 
2 
 
1 NMP 1.15 NMP R.T 20 95 
3 
 
1 NMP 1.15 NMP R.T. 10 95 
a Yield determined by weighing the solid intermediate 46, crystallized upon addition of H2O to the 
crude mixture (1 mL of H2O in 1 mL sample of reaction mixture). b Conditions reproduced from 
literature24,25. c No crystallization occurred. 
 
A second step was coupled using the combination R-S + S-C paths. Two new 
solutions were loaded in the RDS: a 0.6 M solution of potassium hydroxide in 
Methanol/Water 1:1 and a 1.5 M solution of diethylamine (47) in the same solvent mixture. 
Intermediate 46 was generated as reported in Table 3.20, entry 3 and stored in the stand-
by module. The three liquid segments were mixed and conditions for the second step (Li-
2) were screened using the S-C path (Figure 3.30). 
The crude reaction mixture exiting the synthesizer was extracted with hexane and 
NH4Cl/NaCl (1:1) and the residue, after evaporation of the solvent, was dissolved in CDCl3 
and analyzed via 1H NMR. The highest isolated yield was achieved applying 130 °C for 20 
minutes (Table 3.21, entry 6). This result was in accordance with reported literature 
data24,25. 
Crystallization via formation of lidocaine HCl salt: After extraction with NH4Cl/NaCl 
(1:1), the organic layers were concentrated to ≈ 5 mL and 0.2 mL of HCl solution in Et2O 
2 N (2 equiv.) were slowly added. The slurry generated was stirred for 1 h and then filtered 
and washed with n-hexane, achieving 41.971 mg of lidocaine HCl (yield: 62%). Crystals 
of lidocaine HCl were dissolved in CDCl3 and analyzed via 1H NMR. 
Table 3.21. Screening of conditions for the synthesis of lidocaine 40 (Li-2). 
Entry 
 
Conc. 46 (M)a Equiv. 47b T (°C) t Conv. (%)c Yield (%) 
1e 
 
0.5 3 60 20 h 97 81d 
2 
 
0.5 3 60 3.5 h 85 71d 
3 
 
0.5 3 60 20 min -  
4 
 
0.5 Neat (15) 60 20 min -  
5 
 
0.5 3 130 5 min 79 52d 
6 
 
0.5 3 130 20 min 93 62f 
a The concentration of 46 is given assuming a 100% yield in step Li-1 since the second step Li-2 is 
performed directly from the crude mixture of Li-1. b KOH and 47 were both dissolved in H2O/MeOH 
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1:1, then added simultaneously to the crude mixture of Li-1 using the S-C path. c  Conversion was 
estimated via 1H NMR by the ratio of the integrated area of the CH2 peak of 40 (3.29 ppm) and the 
total area of CH2 peaks of 40 + 46 (4.25 ppm)  d Isolated yield after extraction with hexane and 
evaporation. Yield is calculated from the weight of the residue and the conversion. e Test performed 




Figure 3.29. First step of the radial synthesis of lidocaine (Li-1) performed using the R-S pathway. 





Figure 3.30. Second step of the radial synthesis of lidocaine (Li-2) performed using the S-C 
pathway. Starting materials are reported in blue and products in red. 
3.4.2.2 Scale-up of the synthesis of lidocaine (40) in continuous flowi 
The flow synthesis of lidocaine was scaled up using a Vapourtec R2 pump module 
and a 1.6 mL room temperature coil for the first step. Solutions of 44 (1 M in NMP) and 45 
(1.15 M in NMP) were pumped at 0.08 mL/min each to achieve a 10-minute residence 
                                               
i The continuous flow process for the synthesis of lidocaine was developed and performed 
in collaboration with Lucia Anghileri.  
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time. The second step was telescoped pumping a solution of diethylamine 47 (0.75 M) and 
KOH (0.3 M) in methanol/water 1:1 at 0.34 mL/min (total flow rate 0.5 mL/min) through a 
10 mL coil heated at 130 °C by a Vapourtec R4 module (20 min residence time) (Figure 
3.31). The crude reaction mixture exiting the system was collected for 90 minutes (45 mL) 
and was extracted with hexane and NH4Cl/NaCl (1:1). The organic layers were evaporated 
and the residue re-dissolved in 10 mL of hexane. 7.2 mL of HCl solution in Et2O 2 N (2 
equiv.) were slowly added. The slurry generated was stirred for 1 h and then filtered and 
washed with n-hexane, achieving 1.15 g of lidocaine HCl (yield: 59%). Crystals of lidocaine 
HCl were dissolved in CDCl3 and analyzed via 1H NMR. 
 
 
Figure 3.31. Continuous flow synthesis of lidocaine 40. First step: two feeds A and B, pumped by a 
Vapourtec R2 pump module pass through a room temperature coil (PFA, i.d. 0.8 mm). Second step: 
the solution exiting the first reactor is combined with a third feed (C) and passes through a stainless 
steel reactor (i.d. 1 mm) heated at 130 °C by a Vapourtec R4. 
 Synthesis of nifedipine (41) 
Nifedipine is a medication used to treat angina and high blood pressure among 
other ailments47 and it appeared on the list of drugs in shortage in Germany during the 
COVID-19 pandemic36. Traditionally, nifedipine is synthesized in batch through a one-step 
multicomponent reaction by mixing 2-nitrobenzaldehyde (48), methyl acetoacetate (49), 
and methyl 3-aminocrotonate (50) at high temperatures in alcohol solvents38,39 (Scheme 
3.32). This reaction requires several hours and is usually carried out overnight. Performing 
this reaction in flow permitted the safe application of temperatures well above the boiling 
point of the solvent and accelerate the synthesis that is completed in just 1 hour. This is 




Scheme 3.32. Synthesis of nifedipine 41 
3.4.3.1 Optimization of the synthesis of nifedipine (41) in the radial synthesizer 
In the optimization study of this process two solvents were investigated: ethanol 
and methanol. Running the reaction in ethanol resulted in a significant amount of side 
product at high temperature due to transesterification.  
 
Figure 3.32. Process optimization for the synthesis of nifedipine carried out in the radial synthesizer 
using the R-C path. 
Solutions of 2-nitrobenzaldehyde (48), methyl acetoacetate (49) (1.1 equiv.) and 
methyl (2Z)-3-amino-2-butenoate (12) (1 equiv.) in both ethanol and methanol were 
prepared and loaded into the reagent delivery system of the radial synthesizer. The effects 
of temperature and residence time on the conversion of 48 were screened using the R-C 
path (Figure 3.33). Aiming at accelerating the reaction, temperatures from 80 °C to 150 °C 
and a residence time range between 5 minutes and 3 hours were screened. Stop flow 
conditions were applied for longer residence times (see section 2.1.3.2).  
Reaction time decreased as expected with increasing temperature and the best 
conversion was found employing ethanol as solvent (60 minutes residence time at 140 
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°C). However, a high amount of side product was generated at this temperature due to 
transesterification of 41 by ethanol and only a 30% yield of the desired product was 
obtained (Table 3.22 entry 2). This issue was solved by changing the solvent from ethanol 
to methanol (Table 3.22, entry 6). After collection, the solvent was evaporated, and the 
crude was analyzed via 1H NMR. NMR yield (68%) was determined for this product via 1H 
NMR vs 2,2,6,6-tetramethylpiperidine. 
Table 3.22. Conditions screening for the synthesis of nifedipine.a 
Entry 
 
Conc. 48 (M) Solvent T (°C) t (min) Conversion of 48 Yield %b 
1 
 
0.5 EtOH 140 5 45 <5 
2 
 
0.5 EtOH 140 60 >95 30 
3 
 
0.5 MeOH 90 60 71 20 
4 
 
0.5 MeOH 110 60 74 35 
5 
 
0.5 MeOH 130 60 95 55 
6 
 
0.5 MeOH 140 60 96 66 
7 
 
0.5 MeOH 150 60 97 68 
a Conditions screened using the R-C pathway on the synthesizer; the reaction was monitored via 
1H NMR. bYield determined by the ratio of the integrated areas using internal standard (2,2,6,6-




Figure 3.33. Radial synthesis of nifedipine (R-C pathway). Starting materials are reported in blue 




3.4.3.2 Scale-up of the synthesis of nifedipine (41) in continuous flowii 
For the scale-up of this process Vapourtec R2 pump module was used to feed a 
0.5 M solution (25 mL, 12.5 mmol) of 48 (1 eq.), 49 (1.1 equiv.), and 50 (1 equiv.) in 
methanol in a 10 mL heated stainless steel coil reactor (150 °C) at 0.167 mL/min (heating 
module: Vapourtec R4). The starting material was fully consumed, and crude NMR 
showed clean formation of the desired product within 60 minutes (Figure 3.34). The system 
was run for 150 minutes, collecting 25 mL of crude solution. The volume of the crude 
solution was reduced by evaporation to 10~15 mL and crystallization of nifedipine was 
achieved by slowly adding 15 mL of H2O to the crude mixture and stirring for 1 hour. We 
isolated 3.06 g of crystallized nifedipine (41) (71% yield). 
 
Figure 3.34. Continuous flow synthesis of nifedipine carried out using a Vapourtec R2 pump module 
and a PFA reactor coil (10 mL, i.d. 0.8 mm) heated by a Vapourtec R4 module. 
Higher temperatures were screened for this continuous flow process, but despite 
full conversion of the starting material was shown, the yield of nifedipine 41 dropped when 
increasing temperature over 150°C (Table 3.23 and Figure 3.35). 
This confirmed that optimal conditions were those of Table 3.22, entry 6 found with 
the radial synthesizer. 
                                               
ii The continuous flow process for the synthesis of nifedipine was developed and performed 
in collaboration with Dr. Sooyeon Moon. 
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Conc. 48 (M) Solvent T (°C) t (min) Conversion of 48 Yield %b 
1 
 
0.5 EtOH 140 5 45 <5 
2 
 
0.5 EtOH 140 60 >95 30 
3 
 
0.5 MeOH 90 60 71 20 
4 
 
0.5 MeOH 110 60 74 35 
5 
 
0.5 MeOH 130 60 95 55 
6 
 
0.5 MeOH 140 60 96 68 
7 
 
0.5 MeOH 150 60 97 68 
8 c 
 
0.5 MeOH 170 60 98 55 
9 c 
 
0.5 MeOH 190 60 99 38 
athe reaction was monitored via 1H NMR. bYield determined by the ratio of the integrated areas 
using internal standard (2,2,6,6-tetramethylpiperidine) in 1H NMR. c tests performed only in 




Figure 3.35. Reaction results by temperature change at 0.5 M in Methanol, nifedipine: blue = 




















4 Experimental section 
4.1 General chemical information 
Chemicals and solvents were purchased from commercial suppliers and used as 
received. 1H NMR, 13C NMR, and 19F NMR spectra were recorded on a Varian 400 MHz, 
Bruker 400 MHz, Varian, 600 MHz or Bruker 700 MHz spectrometer. Chemical shifts were 
referenced using the residual solvent peak as an internal reference (CDCl3: 7.26 ppm 1H 
NMR, 77.16 ppm 13C NMR; DMSO d6: 2.50 ppm 1H NMR, 39.52 ppm 13C NMR; CD3OD 
3.31 ppm 1H NMR, 49.00 ppm 13C NMR). Multiplicity is indicated as follows: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), tt (triplet of triplet). 
IR spectra were recorded on a Mettler Toledo Flow-IR™ and processed with its own 
software (ICIR), subtracting the previously recorded solvent spectra. High-resolution mass 
spectra were obtained using a 6210 ESI-TOF mass spectrometer (Agilent). 
All the tests were performed using 0.5 mL sample loops (on valve C and D) and 
0.5 mL standby loop (on valve H). The heated reactor is a 20 mL coil connected to port 14 
of divergent valve E (reactor inlet) and port 14 of convergent valve F (reactor outlet) and 
heated by a Vapourtec R4 heating module. the photoreactor is a 10 mL FEP coil irradiated 
by a 420 nm LED light source, connected to port 12 of divergent valve E (reactor inlet) and 
port 12 of convergent valve F (reactor outlet). Final products are collected in either a 
pressurized or unpressurized vessel connected to the forwarding valve G.   
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4.2 Compound characterization 
2,6-difluorobenzyl azide (2) 
 
Compound 2 was prepared from 2,6-difluorobenzyl bromide 1 and sodium azide 
following the procedure described in section 3.1.1.1. Following collection, the solvent was 
evaporated, and the residue was fully dissolved in 0.5 mL of CDCl3. 1H NMR (400 MHz, 
Chloroform-d) δ 7.33 (tt, J = 8.5, 6.5 Hz, 1H), 7.02 – 6.90 (m, 2H), 4.44 (d, J = 1.4 Hz, 2H). 




Compound 4 was prepared from methyl propiolate 3 and aqueous ammonia 
following the procedure described in section 3.1.1.2. Following collection, the solvent was 
evaporated, and the residue was fully dissolved in 0.5 mL deuterated methanol. 1H NMR 
(400 MHz, Methanol-d4) δ 3.59 (s, 1H). 13C NMR (101 MHz, Methanol-d4) δ 156.9, 77.6, 
76.7. These data are in accordance with those previously published49.  
 
1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide (rufinamide 5)  
 
Compound 5 was prepared from 2,6-difluorobenzyl azide 2, propiolamide 4, and 
catalytic amount of copper iodide following the procedure described on section 3.1.1.3. 
The product crystallizes spontaneously upon collection. Crystals were dissolved in 0.5 mL 
deuterated DMSO. 1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 1H), 7.88 (s, 1H), 7.59 – 7.44 
(m, 2H), 7.26 – 7.13 (m, 2H), 5.72 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 162.1 (d, J = 
7.4 Hz), 161.3, 159.6 (d, J = 7.4 Hz), 142.9, 131.9 (t, J = 10.4 Hz), 126.9, 112.1 (d, J = 5.7 
Hz), 111.9 (d, J = 5.6 Hz), 111.1 (t, J = 19.1 Hz), 41.2 (t, J = 3.8 Hz). These data are in 




Methyl 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylate (6) 
 
Compound 6 was prepared from 2,6-difluorobenzyl azide 2, methyl propiolate 3, 
and catalytic amount of copper iodide following the procedure described in section 3.1.2.2. 
Following collection, the product was crystallized by water. Crystals were dissolved in 0.5 
mL deuterated DMSO. 1H NMR (400 MHz, DMSO-d6) δ 8.90 (s, 1H), 7.51 (tt, J = 8.5, 6.7 
Hz, 1H), 7.25 – 7.09 (m, 2H), 5.75 (s, 2H), 3.80 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 
162.1 (d, J = 7.3 Hz), 160.6, 159.6 (d, J = 7.3 Hz), 138.5, 132.0 (t, J = 10.5 Hz), 129.6, 
112.1 (d, J = 5.6 Hz), 111.9 (d, J = 5.5 Hz), 110.9 (t, J = 19.0 Hz), 51.9, 41.4 (t, J = 3.7 




Compound 12 was prepared from benzyl azide 23, propiolamide 4, and catalytic 
amount of copper iodide following the procedure described in section 3.2.1.3. Following 
collection, the product was crystallized by water. Crystals were dissolved in 0.5 mL 
deuterated DMSO. 1H NMR (400 MHz, DMSO-d6) δ 8.61 (s, 1H), 7.89 (s, 1H), 7.49 (s, 
1H), 7.43 – 7.28 (m, 5H), 5.64 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 161.5, 143.2, 
135.8, 128.9, 128.3, 128.0, 126.7, 53.1. m/z (HRMS+) for C10H10N4ONa+ [M+Na]+ calcd. 




Compound 13 was prepared from 2-(azidomethyl)naphthalene 24, propiolamide 4, 
and catalytic amount of copper iodide following the procedure described in section 3.2.1.4. 
Following collection, the product was crystallized by water. Crystals were dissolved in 0.5 
mL of deuterated DMSO. 1H NMR (400 MHz, DMSO-d6) δ 8.67 (s, 1H), 7.99 – 7.85 (m, 
5H), 7.58 – 7.44 (m, 4H), 5.82 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 161.5, 143.2, 
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133.3, 132.8, 132.6, 128.6, 127.9, 127.7, 127.0, 126.9, 126.7, 126.6, 125.8, 53.2. m/z 




Compound 14 was prepared from intermediate 6 and ethylamine (70% solution in 
water), following the procedure described in section 3.2.2.2. Following collection, the 
product was crystallized by water. Crystals were dissolved in 0.5 mL deuterated DMSO. 
1H NMR (400 MHz, DMSO-d6) δ 8.54 (d, J = 11.8 Hz, 2H), 7.52 (tt, J = 8.5, 6.7 Hz, 1H), 
7.27 – 7.12 (m, 2H), 5.72 (s, 2H), 3.24 (qd, J = 7.1, 5.7 Hz, 2H), 1.07 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ 162.1 (d, J = 7.3 Hz), 159.6 (d, J = 7.3 Hz), 159.2, 142.9, 
131.8 (d, J = 10.6 Hz), 126.6, 112.2, 111.9, 111.2 (d, J = 19.1 Hz), 41.2, 33.3, 14.9. 




Compound 15 was prepared from intermediate 25 and ethylamine (70% solution 
in water), following the procedure described in section 3.2.3.7. Following collection, the 
product was crystallized by water. Crystals were dissolved in 0.5 mL deuterated DMSO. 
1H NMR (400 MHz, DMSO-d6) δ 8.62 (s, 1H), 8.55 (t, J = 5.9 Hz, 1H), 7.44 – 7.25 (m, 5H), 
5.64 (s, 2H), 3.25 (qd, J = 7.2, 5.7 Hz, 2H), 1.08 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, 
DMSO-d6) δ 159.4, 143.3, 135.8, 128.9, 128.3, 128.0, 126.5, 53.1, 33.3, 14.9. m/z 




Compound 16 was prepared from intermediate 26 and ethylamine (70% w/w 
solution in water), following the procedure described in section 3.2.3.8. Following 
collection, the product was crystallized by water. Crystals were dissolved in 0.5 mL 
deuterated DMSO. 1H NMR (400 MHz, DMSO-d6) δ 8.68 (s, 1H), 8.55 (t, J = 5.9 Hz, 1H), 
131 
 
8.00 – 7.85 (m, 4H), 7.61 – 7.40 (m, 3H), 5.81 (s, 2H), 3.32 – 3.16 (m, 2H), 1.08 (t, J = 7.1 
Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 159.3, 143.3, 133.3, 132.8, 132.6, 128.6, 127.9, 
127.7, 127.0, 126.7, 126.6, 126.5, 125.7, 53.3, 33.3, 14.9. m/z (HRMS+) for C17H16N4ONa+ 




Compound 17 was prepared from intermediate 6, following the procedure 
described in section 3.2.2.1. Following collection, the product was crystallized by water. 
Crystals were dissolved in 0.5 mL deuterated DMSO. 1H NMR (400 MHz, DMSO-d6) δ 
8.54 (d, J = 19.3 Hz, 2H), 7.52 (tt, J = 8.4, 6.7 Hz, 1H), 7.19 (t, J = 8.1 Hz, 2H), 5.72 (s, 
2H), 3.17 (dt, J = 7.6, 6.2 Hz, 2H), 1.49 (h, J = 7.4 Hz, 2H), 0.84 (t, J = 7.4 Hz, 3H). 13C 
NMR (101 MHz, DMSO-d6) δ 162.1 (d, J = 7.3 Hz), 159.6 (d, J = 7.3 Hz), 159.4, 142.9, 
131.9 (t, J = 10.4 Hz), 126.6, 112.1 (d, J = 5.7 Hz), 111.9 (d, J = 5.6 Hz), 111.1 (t, J = 19.1 
Hz), 41.2 (t, J = 3.9 Hz), 40.2, 22.5, 11.4. m/z (HRMS+) for C13H14F2N4ONa+ [M+Na]+ calcd. 




Compound 18 was prepared from intermediate 25 and propylamine, following the 
procedure described in section 3.2.3.3. Following collection, the product was crystallized 
by water. Crystals were dissolved in 0.5 mL deuterated DMSO. 1H NMR (400 MHz, DMSO-
d6) δ 8.62 (s, 1H), 8.53 (t, J = 6.0 Hz, 1H), 7.44 – 7.28 (m, 5H), 5.64 (s, 2H), 3.18 (dt, J = 
7.6, 6.2 Hz, 2H), 1.50 (h, J = 7.4 Hz, 2H), 0.84 (t, J = 7.4 Hz, 3H).13C NMR (101 MHz, 
DMSO-d6) δ 159.5, 143.2, 135.8, 128.9, 128.3, 128.0, 126.5, 53.1, 40.2, 22.5, 11.4. m/z 







Compound 19 was prepared from intermediate 26 and propylamine, following the 
procedure described in section 3.2.3.4. Following collection, the product was crystallized 
by water. Crystals were dissolved in 0.5 mL deuterated DMSO. 1H NMR (400 MHz, DMSO-
d6) δ 8.68 (s, 1H), 8.54 (t, J = 6.0 Hz, 1H), 8.00 – 7.84 (m, 4H), 7.61 – 7.41 (m, 3H), 5.81 
(s, 2H), 3.18 (dt, J = 7.7, 6.2 Hz, 2H), 1.50 (h, J = 7.4 Hz, 2H), 0.84 (t, J = 7.4 Hz, 4H). 13C 
NMR (101 MHz, DMSO-d6) δ 159.6, 143.3, 133.3, 132.8, 132.6, 128.6, 127.9, 127.7, 
127.1, 126.7, 126.6, 126.6, 125.8, 53.3, 40.2, 22.5, 11.4. m/z (HRMS+) for C17H18N4ONa+ 




Compound 20 was prepared from intermediate 6, allylamine, following the 
procedure described in section 3.2.2.3. Following collection, the product was crystallized 
by water. Crystals were dissolved in 0.5 mL deuterated DMSO 1H NMR (400 MHz, DMSO-
d6) δ 8.68 (t, J = 6.0 Hz, 1H), 8.60 (s, 1H), 7.52 (tt, J = 8.5, 6.7 Hz, 1H), 7.19 (t, J = 8.1 Hz, 
2H), 5.85 (ddt, J = 17.2, 10.3, 5.2 Hz, 1H), 5.73 (s, 2H), 5.20 – 4.97 (m, 2H), 3.85 (tt, J = 
5.6, 1.7 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 162.1 (d, J = 7.2 Hz), 159.6 (d, J = 7.3 
Hz), 159.3, 142.7, 135.3, 131.9 (t, J = 10.4 Hz), 126.7, 115.1, 112.1 (d, J = 5.7 Hz), 111.9 
(d, J = 5.6 Hz), 111.1 (t, J = 19.1 Hz), 41.3 (t, J = 3.8 Hz), 40.8. m/z (HRMS+) for 




Compound 21 was prepared from intermediate 25 and allylamine, following the 
procedure described in section 3.2.3.6. Following collection, the product was crystallized 
by water. Crystals were dissolved in 0.5 mL deuterated DMSO 1H NMR (400 MHz, DMSO-
d6) δ 8.68 (d, J = 19.9 Hz, 1H), 7.48 – 7.26 (m, 3H), 5.85 (ddt, J = 17.2, 10.3, 5.2 Hz, 1H), 
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5.65 (s, 1H), 5.20 – 4.96 (m, 1H), 3.85 (td, J = 5.6, 2.8 Hz, 1H). 13C NMR (101 MHz, DMSO-
d6) δ 159.5, 143.0, 135.7, 135.3, 128.9, 128.3, 128.1, 126.6, 115.1, 53.1, 40.8. m/z 




Compound 22 was prepared from intermediate 26 and allylamine, following the 
procedure described in section 3.2.3.6. Following collection, the product was crystallized 
by water. Crystals were dissolved in 0.5 mL deuterated DMSO 1H NMR (400 MHz, DMSO-
d6) δ 8.70 (d, J = 2.9 Hz, 2H), 7.97 – 7.86 (m, 4H), 7.57 – 7.45 (m, 3H), 5.90 – 5.75 (m, 
3H), 5.17 – 4.98 (m, 2H), 3.85 (tt, J = 5.6, 1.7 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 
159.5, 143.0, 135.3, 133.2, 132.8, 132.6, 128.6, 127.9, 127.7, 127.1, 126.7, 126.7, 126.6, 
125.8, 115.1, 53.3, 40.8. m/z (HRMS+) for C17H16N4ONa+ [M+Na]+ calcd. 315.1216, found 
315.1233. 
 
Benzyl azide (23) 
 
Compound 23 was prepared from benzyl bromide 7 and sodium azide following 
the procedure described in section 3.2.1.1 using deuterated water, deuterated methanol, 
and non-deuterated acetonitrile as solvents. Intermediate 23 was not isolated, a sample 
of 0.25 mL of solution was analyzed after addition of 0.25 mL of deuterated DMSO. 1H 
NMR (400 MHz, DMSO-d6) δ 7.39 – 7.21 (m, 5H), 4.32 (s, 2H). These data are in 




Compound 24 was prepared from 2-(bromomethyl)naphthalene 8 and sodium 
azide following the procedure described in section 3.2.1.2. Following collection, the solvent 
was evaporated, and the residue was fully dissolved in 0.5 mL of deuterated DMSO. 1H 
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NMR (400 MHz, DMSO-d6) δ 8.01 – 7.83 (m, 4H), 7.58 – 7.44 (m, 3H), 4.60 (s, 2H). These 
data are in accordance with those previously published53. 
Methyl 1-benzyl-1H-1,2,3-triazole-4-carboxylate (25) 
 
Compound 25 was prepared from benzyl azide 23, methyl propiolate 3, and 
catalytic amount of copper iodide following the procedure described in section 3.2.3.1. 
Following collection, the product was crystallized by water. Crystals were dissolved in 0.5 
mL deuterated DMSO. 1H NMR (400 MHz, DMSO-d6) δ 8.92 (s, 1H), 7.43 – 7.28 (m, 5H), 
5.67 (s, 2H), 3.82 (s, 3H). These data are in accordance with those previously published54. 
 
Methyl 1-(naphthalen-2-ylmethyl)-1H-1,2,3-triazole-4-carboxylate (26) 
 
Compound 26 was prepared from 2-(azidomethyl)naphthalene 24, methyl 
propiolate 3, and catalytic amount of copper iodide following the procedure described in 
section 3.2.3.2. Following collection, the product was crystallized by water. Crystals were 
dissolved in 0.5 mL deuterated DMSO. 1H NMR (400 MHz, DMSO-d6) δ 8.97 (s, 1H), 7.98 
– 7.84 (m, 4H), 7.59 – 7.43 (m, 3H), 5.83 (s, 2H), 3.82 (s, 3H). 13C NMR (101 MHz, DMSO-
d6) δ 160.7, 138.9, 133.0, 132.8, 132.6, 129.5, 128.6, 127.9, 127.7, 127.1, 126.7, 126.6, 





Compound 35 was prepared from 4-bromobenzotrifluoride (30) and pyrrolidine, 
with catalytic amount of NiBr2 ● 3H2O 5% and Ir cat 0.2% as described in section 3.3.1.1. 
The product purified by column chromatography was dissolved in 0.5 mL CDCl3. 1H NMR 
(400 MHz, Chloroform-d) δ 7.43 (d, J = 8.5 Hz, 2H), 6.55 (d, J = 8.5 Hz, 2H), 3.37 – 3.26 







Compound 36 was prepared from 4-bromobenzotrifluoride (30) and pyrrolidin-3-ol, 
with catalytic amount of NiBr2 ● 3H2O 5% and Ir cat 0.2% as described in section 3.3.1.3. 
The product purified by column chromatography was dissolved in 0.5 mL CDCl3, 1H NMR 
(400 MHz, Chloroform-d) δ 7.44 (d, J = 8.4 Hz, 2H), 6.55 (d, J = 8.4 Hz, 2H), 4.63 (s, 1H), 
3.60 – 3.20 (m, 4H), 2.25 – 2.00 (m, 2H), 1.85 (s, 1H).  13C NMR (101 MHz, Chloroform-
d) δ 149.7, 128.6, 126.6 (q, J = 3.8 Hz), 124.0, 117.4 (q, J = 32.5 Hz), 115.5, 111.1, 71.2, 





Compound 37 was prepared from 4-bromobenzotrifluoride (30) and piperidin-4-ol, 
with catalytic amount of NiBr2 ● 3H2O 5% and Ir cat 0.2% as described in section 3.3.1.4. 
The product purified by column chromatography was dissolved in 0.5 mL CDCl3, 1H NMR 
(400 MHz, Chloroform-d) δ 7.65 – 7.38 (m, 2H), 6.91 (ddd, J = 15.5, 8.9, 2.6 Hz, 2H), 3.90 
(s, 1H), 3.75 – 3.54 (m, 2H), 3.03 (ddt, J = 13.0, 10.1, 3.0 Hz, 2H), 1.99 (td, J = 8.4, 7.2, 
3.9 Hz, 2H), 1.67 (dddt, J = 12.8, 9.6, 6.3, 3.2 Hz, 2H). 13C NMR (101 MHz, Chloroform-d) 
δ 153.1, 127.2 (d, J = 3.7 Hz), 126.6 (q, J = 3.8 Hz), 123.6, 120.0, 115.6, 114.9, 67.8, 46.1, 
33.8. m/z (HRMS+) for C11H14F3NOH+ [M+H]+ calcd. 246.1110, found 246.1112. 
1-(4-bromophenyl)pyrrolidine (38) 
 
Compound 38 was prepared from 1,4-dibromobenzene (31) and pyrrolidine, with 
catalytic amount of NiBr2 ● 3H2O 5% and Ir cat 0.2% as described in section 3.3.1.2. The 
product purified by column chromatography was dissolved in 0.5 mL CDCl3, 1H NMR (400 
MHz, Chloroform-d) δ 7.43 – 7.14 (m, 2H), 6.58 – 6.30 (m, 2H), 3.36 – 3.14 (m, 4H), 2.12 




N-acetyl-para-aminophenol (paracetamol 39) 
 
Compound 39 was prepared from 4-aminophenol (42) and acetic anhydride (43) 
as described in section 3.4.2.2. The product purified by crystallization was dissolved in 0.5 
mL of deuterated DMSO: 1H NMR (400 MHz, DMSO) δ 9.66 (s, 1H), 9.16 (s, 1H), 7.33 (d, 
J = 8.8 Hz, 2H), 6.67 (d, J = 8.8 Hz, 2H), 1.97 (s, 3H). These data are in accordance with 
those previously published56. 
 
N-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide (lidocaine 40) 
 
Compound 40 was prepared from intermediate 46 and diethylamine 47 as 
described in section 3.4.2.2. After extraction the residue was dissolved in CDCl3: 1H NMR 
(400 MHz, CDCl3) δ 8.94 (s, 1H), 7.10 – 7.08 (m, 3H), 3.23 (s, 2H), 2.70 (q, J = 7.1 Hz, 
4H), 2.23 (s, 6H), 1.14 (t, J = 7.1 Hz, 6H). These data are in accordance with those 
previously published24. Compound 40 was purified by crystallization as HCl salt and was 
then dissolved in CDCl3: 1H NMR (400 MHz, CDCl3) δ 7.07 – 7.00 (m, 3H), 4.32 (s, 2H), 
3.62 – 3.34 (m, 4H), 2.27 (s, 6H), 1.54 (t, J = 7.3 Hz, 6H). These data are in accordance 





Compound 41 was prepared from 2-nitrobenzaldehyde (48), methyl acetoacetate 
(49), and methyl 3-aminocrotonate (50) as described in section 3.4.3.2. The product 
purified by crystallization was dissolved in 0.5 mL of CDCl3: 1H NMR (400 MHz, CDCl3) δ 
7.61 (dd, J = 8.0, 1.4 Hz, 1H), 7.44 (dd, J = 8.0, 1.6 Hz, 1H), 7.38 (td, J = 7.6, 1.4 Hz, 1H), 
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7.21 – 7.15 (m, 1H), 5.85 (s, 1H), 5.65 (s, 1H), 3.52 (s, 6H), 2.26 (s, 6H). These data are 




Compound 46 was synthesized from 2,6-dimethyl aniline (44) and chloroacetyl 
chloride (45) as described in section 3.4.2.2. The product purified by crystallization with 
water and upon filtration was dissolved in 0.5 mL of CDCl3: 1H NMR (400 MHz, CDCl3) δ 
7.87 (s, 1H), 7.20 – 7.04 (m, 3H), 4.25 (s, 2H), 2.24 (s, 6H). These data are in accordance 







5 Conclusions and perspective 
A fully automated, remotely accessible instrument capable of synthesizing small 
organic molecules based on a radial arrangement of continuous flow modules has been 
developed. The sequential, non-simultaneous nature of multistep radial synthesis is more 
versatile than linear or iterative synthetic approaches since each step of a multistep 
process is functionally independent from the others. Thereby, reactors can be reused at 
different temperatures and flow rates while intermediates can be stored for convergent 
syntheses and multistep optimizations.  
This is the first automated platform capable of exploring both linear and convergent 
synthetic routes, performing concentration and solvent screening inline, and allowing for 
equipment reutilization, also at variable conditions, within the same process, all without 
physical reconfiguration.  
The radial synthesizer showed high flexibility over different reaction conditions for 
single or multistep syntheses, good reproducibility of results and ability to synthesize 
libraries of compounds through combination of a set of starting materials and reagents in 
different orders and under different conditions.  
Its synthetic and analytical capabilities could be easily expanded by integration of 
new modules that proved to be operationally simple. Finally, the equivalence between 
radial and continuous flow was demonstrated, thus establishing the radial synthesizer as 
a powerful tool for process discovery. Reaction conditions optimized using the radial 
synthesizer could be translated without any modification in a commercially available 
continuous flow system (Vapourtec R2 and R4), for scale-up and continuous operation.  
These capabilities were demonstrated through the comparison of two alternative 
synthetic routes for the API rufinamide (convergent and linear, section 3.1), the generation 
of a library of twelve derivatives (section 3.2), the integration of a photochemical module 
for metallaphotoredox C-N cross-couplings and of a flow-NMR spectrometer for 
determination of inline NMR yield29 (section 3.3). Finally, the optimization and scale-up of 
the synthesis of three drugs (paracetamol, lidocaine and nifedipine) demonstrated the 
equivalence between radial and continuous flow (section 3.4). 
The radial synthesizer utilizes commercially available equipment and hardware and 
can be operated in manual or fully automated mode through a software interface. Given 
the remarkable and constantly growing number of flow modules already existing, from 
home-made devices to commercially available systems, the capabilities of the radial 
synthesizer can potentially be expanded even further. New synthetic modules can be 
integrated in the central station of the instrument granting access to new chemistries.  
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As the equivalence between flow modules linked in radial and linear telescoped 
arrangement was already successfully proved, the next easiest exhibition of the potential 
of radial synthesis could be the demonstration of the same equivalence with iterative 
synthesis (section 1.3.2). This could be done by integrating a continuous stirred tank 
reactor (CSTR) containing resin beads for the solid-phase synthesis of biopolymers6,7,8 or 
cartridges and packed bed modules for the iterative cross-coupling and purification of 
MIDA boronates27. If that would prove possible, we would have in a single instrument the 
capability to explore all the different approaches to organic synthesis and performing high 
throughput, automated condition screening of extremely diverse processes, and 
potentially the ability to perform building block synthesis and coupling within the same 
automated platform.  
Another future goal to expand the applicability of the radial synthesizer would be 
the introduction of purification modules. The radial synthesizer is suited for the 
development of a hybrid platform that bridges flow and batch technologies by taking the 
best elements from both. Extraction, crystallization, and solvent-switch modules can be 
designed to be integrated in the central station to purify and isolate final products or 
synthetic intermediates. 
Besides the evolution of the hardware, an effort must be taken for the 
implementation of algorithms for data processing and machine learning. Such a versatile 
automated platform can be used for the generation of large data sets of highly reproducible 
and data-rich synthetic procedures, including positive and negative results.  
Compared to conventional continuous flow chemistry, that employs a large amount 
of material for each test, the radial synthesizer works with small volumes of solutions that 
can be miniaturized even further, allowing for the production of sufficient data in an 
automated manner, within a reasonable time frame and with minimum waste of material. 
Automated systems, in general, ensure reproducibility because they reduce the 
error introduced by manual operations. A given input instruction, in principle, should be 
operated in the same way on an equivalent system, nevertheless each existing system 
nowadays relies on different protocols, resulting in a lack of standardization that limits the 
potential of automation applied to chemistry. Scientists have already identified and tried to 
address this problem, proposing a general programming language for chemical 
operations2. The implementation of software based on a universal language could bridge 
the gap between the many already existing automated synthesizers based on batch2, 
flow24,25,27,29 or solid-phase synthesis6,7,8, thus framing the radial synthesizer within the 
context of a big network of automated platforms using the same modules and generating 
transferable universal protocols for chemical synthesis. 
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As a whole, these platforms for automated synthesis could reshape how research 
is conducted. Since such systems can be operated remotely, it is possible to envision the 
creation of “chemistry server farms”, intended as facilities containing hundreds of 
automated platforms, which scientists could control from anywhere in the world. This would 
truly standardize and democratize research, overcoming economic and geographic 









6 References  
1) Milo, A. Science 2019, 363, 6423, 122–123. 
2) Steiner, S.; Wolf, J.; Glatzel, S.; Andreou, A.; Granda, J. M.; Keenan, G.; Hinkley, 
T.; et al. Science 2019, 363, 6423. DOI: 10.1126/science.aav2211. 
3) Burger, B.; Maffettone, P. M.; Gusev, V. V.; Aitchison, C. M.; Bai, Y.; Wang, X.; Li, 
X.; et al. Nature 2020, 583, 237–241. 
4) Plutschack, M. B.; Pieber, B.; Gilmore, K.; Seeberger, P. H. Chem. Rev. 2017, 117, 
11796–11893. 
5) Trojanowicz, M. Molecules 2020, 25, 1434; DOI: 10.3390/molecules25061434 
6) Merrifield, R. B. Science 1965,150, 178–185. 
7) Alvarado-Urbina, G.; Sathe, G. M.; Liu, W. C.; Gillen, M. F.; Duck, P. D.; Bender, 
R.; Ogilvie, K. K. Science 1981, 214, 270–274. 
8) Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. Science 2001, 291, 1523–1527. 
9) Guidi, M.; Seeberger, P. H.; Gilmore, K. Chem. Soc. Rev. 2020, DOI: 
10.1039/c9cs00832b 
10) Sambiagio, C.; Noël, T. Trends Chem. 2020, 2, 92–106.  
11) Dallinger, D.; Gutmann, B.; Kappe, C. O. Acc. Chem. Res. 2020, 53, 7, 1330–1341. 
12) Yoshida, J.; Nagaki, A.; Yamada, T. Chem. Eur. J. 2008, 14, 7450–7459. 
13) Yoshida, J.; Takahashia, Y.; Nagakia, A. Chem. Commun. 2013, 49, 9896 – 9904. 
14) Su, Y.; Kuijpers, K.; Hessel, V.; Noël, T. React. Chem. Eng. 2016, 1, 73−81. 
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7 Appendix: NMR spectra  
 
Figure 6.1. 1H NMR 2 
 
 





Figure 6.3. 1H NMR 4 
 
 





Figure 6.5. 1H NMR 5 
 
 





Figure 6.7. 1H NMR 6 
 
 





Figure 6.9. 1H NMR 12 
 
 





Figure 6.11. 1H NMR 13 
 
 





Figure 6.13. 1H NMR 14 
 
 





Figure 6.15. 1H NMR 15 
 
 





Figure 6.17. 1H NMR 16 
 
 





Figure 6.19. 1H NMR 17 
 
 





Figure 6.21. 1H NMR 18 
 
 





Figure 6.23. 1H NMR 19 
 
 





Figure 6.25. 1H NMR 20 
 
 





Figure 6.27. 1H NMR 21 
 
 





Figure 6.29. 1H NMR 22 
 
 










Figure 6.32. 1H NMR 24 
 
 









Figure 6.35. 1H NMR 26 
 
 









Figure 6.38. 1H NMR 36 
 
 









Figure 6.41. 1H NMR 37 
 
 














Figure 6.45. 1H NMR 39 
 
 




Figure 6.47. 1H NMR 40 HCl 
 
 




Figure 6.49. 1H NMR 46 
